Tokushima University / Educator and Researcher Directory --- Teraoku, Hiroki

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Youichiro Kawashita, Yuji Morine, Yu Saitou, Chie Takasu, Tetsuya Ikemoto, Shuichi Iwahashi, Hiroki Teraoku, Masato Yoshikawa, Satoru Imura, Toshiyuki Yagi and Mitsuo Shimada : Role of heat shock factor 1 expression in the microenvironment of intrahepatic cholangiocarcinomas., Journal of Gastroenterology and Hepatology, Vol.33, No.7, 1407-1412, 2018. (Summary) Heat shock factor 1 (HSF1), a master regulator of heat shock response, has been shown to play a multifaceted role in cancer progression. However, the clinical significance and biological effect of HSF1 expression in intrahepatic cholangiocarcinoma (IHCC) remain unknown. Forty-nine patients with IHCC who underwent hepatic resection were enrolled in this study. HSF1 expression in tumor tissue was determined by immunohistochemistry, and patients were divided into two groups, those with high (n = 20) and low (n = 29) HSF1 expression. Clinicopathological factors including prognosis were compared in these two groups. HSF1 expression was significantly higher in tumors than in normal tissue. The overall survival rate was significantly lower in patients with high than low HSF1. Multivariate analysis showed that high HSF1 expression was a factor independently prognostic of patient survival. High HSF1 expression in tumor tissues may be a prognostic biomarker in patients with IHCC. (Keyword) Adult / Aged / Aged, 80 and over / Bile Duct Neoplasms / Cell Line, Tumor / Cholangiocarcinoma / Disease Progression / Female / Gene Expression / Heat Shock Transcription Factors / Humans / Immunohistochemistry / Male / Middle Aged / Multivariate Analysis / Prognosis / Survival Rate / Tumor Microenvironment (Link to Publication Site) ● Publication site (DOI): 10.1111/jgh.14078 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29278438 ● Summary page in Scopus @ Elsevier: 2-s2.0-85043330492 (DOI: 10.1111/jgh.14078, PubMed: 29278438, Elsevier: Scopus)
2.	Satoru Imura, Hiroki Teraoku, Masato Yoshikawa, Daichi Ishikawa, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Potential predictive factors for microvascular invasion in hepatocellular carcinoma classified within the Milan criteria., International Journal of Clinical Oncology, Vol.23, No.1, 98-103, 2018. (Summary) Microvascular invasion (mvi) is an important risk factor for recurrent hepatocellular carcinoma (HCC), even after curative liver resection or orthotopic liver transplantation. However, mvi is difficult to detect preoperatively. The aim of this study was to clarify the risk factors of postoperative recurrence and investigate predictive factors of mvi before hepatectomy for HCC classified within the Milan criteria. One hundred fifty-nine patients with hepatocellular carcinoma (HCC) classified within the Milan criteria, who underwent hepatectomy, were enrolled in this study. We investigated the risk factors of recurrence. In addition, we divided them into two groups: mvi-negative group and mvi-positive group, based on pathological findings after surgery. We compared the clinicopathological factors between the two groups and determined the risk factors for mvi. Overall survival rate at 1, 3, and 5 years were 91.6%, 80.5%, and 74.9%, and the recurrence-free survival rate at 1, 3, and 5-years were 72.3%, 51.6%, and 37.2%. Risk factor analysis for tumor recurrence revealed that total bilirubin, albumin, ICGR15, AFP-L3, tumor number, mvi, and tumor stage had a significant predictive value. Multivariate analysis revealed that tumor number and mvi were significant independent risk factors for tumor recurrence. Predictive analysis for risk factors of mvi revealed that multiple tumors and AFP-L3 > 10% were significant independent risk factors for mvi in HCC classified within the Milan criteria. The mvi was one of the independent risk factors for tumor recurrence in HCC classified within the Milan criteria. Multiple tumors and high AFP-L3 value were independent predictive factors for mvi. (Keyword) Aged / Bilirubin / Carcinoma, Hepatocellular / Disease-Free Survival / Female / Hepatectomy / Humans / Liver Neoplasms / Male / Middle Aged / Multivariate Analysis / Neoplasm Recurrence, Local / Retrospective Studies / Risk Factors / Survival Rate (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-017-1189-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28875240 ● Summary page in Scopus @ Elsevier: 2-s2.0-85028981662 (DOI: 10.1007/s10147-017-1189-8, PubMed: 28875240, Elsevier: Scopus)
3.	Toshiaki Yoshimoto, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Daichi Ishikawa, Hiroki Teraoku, Yoshimi Bando and Mitsuo Shimada : The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma: Experience of Conversion and Salvage Hepatectomy., Anticancer Research, Vol.38, No.1, 501-507, 2018. (Summary) We report the outcomes of sorafenib therapy for advanced hepatocellular carcinoma (HCC) in our Department. Thirty-eight patients with unresectable HCC who were administrated sorafenib from 2009 to 2015 were investigated retrospectively. The 1-year overall survival rate was 59.3%. The macroscopic vascular invasion and response rate were independent prognostic factors of survival. Surgical resection after sorafenib achieved long-term survival in two cases. Case 1: A patient with locally unresectable HCC showed significant response induced by sorafenib, which allowed complete surgical resection. This tumor tested positive for FGF4. Case 2: A patient with a history of hepatectomy for HCC had multiple distant metastases. Most lesions were reduced in size after sorafenib therapy and new lesions in the remnant liver and residual lung metastases were resected. The sorafenib-resistant lesions were negative for FGF4. Sorafenib combined with surgical resection is a feasible option in advanced HCC patients, if sorafenib has been effective. (Keyword) Adult / Aged / Aged, 80 and over / Antineoplastic Agents / Carcinoma, Hepatocellular / Combined Modality Therapy / Female / Fibroblast Growth Factor 4 / Hepatectomy / Hepatitis B / Humans / Liver Neoplasms / Male / Middle Aged / Niacinamide / Phenylurea Compounds / Retrospective Studies / Salvage Therapy / Sorafenib / Survival Rate (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.12250 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29277815 ● Summary page in Scopus @ Elsevier: 2-s2.0-85039796842 (DOI: 10.21873/anticanres.12250, PubMed: 29277815, Elsevier: Scopus)

Academic Paper (Unrefereed Paper):

1.	Shuhai Chen, Yu Saitou, Yuhei Waki, Tetsuya Ikemoto, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : Generation of Highly Functional Hepatocyte-like Organoids from Human Adipose-Derived Mesenchymal Stem Cells Cultured with Endothelial Cells., Cells, Vol.13, No.6, 2024. (Summary) Previously, we successfully established a highly functional, three-dimensional hepatocyte-like cell (3D-HLC) model from adipose-derived mesenchymal stem cells (ADSCs) via a three-step differentiation protocol. The aim of the present study was to investigate whether generating hepatocyte-like organoids (H-organoids) by adding endothelial cells further improved the liver-like functionality of 3D-HLCs and to assess H-organoids' immunogenicity properties. Genes representing liver maturation and function were detected by quantitative reverse transcription-PCR analysis. The expression of hepatic maturation proteins was measured using immunofluorescence staining. Cytochrome P (CYP)450 metabolism activity and ammonia metabolism tests were used to assess liver function. H-organoids were successfully established by adding human umbilical vein endothelial cells at the beginning of the definitive endoderm stage in our 3D differentiation protocol. The gene expression of alpha-1 antitrypsin, carbamoyl-phosphate synthase 1, and apolipoprotein E, which represent liver maturation state and function, was higher in H-organoids than non-organoid 3D-HLCs. H-organoids possessed higher CYP3A4 metabolism activity and comparable ammonia metabolism capacity than 3D-HLCs. Moreover, although H-organoids expressed human leukocyte antigen class I, they expressed little human leukocyte antigen class II, cluster of differentiation (CD)40, CD80, CD86, and programmed cell death ligand 1, suggesting their immunogenicity properties were not significantly upregulated during differentiation from ADSCs. In conclusion, we successfully established an H-organoid model with higher liver-like functionality than previously established 3D-HLCs and comparable immunogenicity to ADSCs. (Keyword) Humans / Ammonia / Hepatocytes / Human Umbilical Vein Endothelial Cells / Mesenchymal Stem Cells / Organoids / HLA Antigens (Link to Publication Site) ● Publication site (DOI): 10.3390/cells13060547 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38534391 ● Search Scopus @ Elsevier (PMID): 38534391 ● Search Scopus @ Elsevier (DOI): 10.3390/cells13060547 (DOI: 10.3390/cells13060547, PubMed: 38534391)
2.	Yuhei Waki, Yuji Morine, Takayuki Noma, Chie Takasu, Hiroki Teraoku, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto and Mitsuo Shimada : Association between high expression of intratumoral fibroblast activation protein and survival in patients with intrahepatic cholangiocarcinoma., BMC Gastroenterology, Vol.23, No.1, 415, 2023. (Summary) Cancer-associated fibroblasts (CAFs) have been reported to exhibit protumorigenic effects. Among the well-known CAF markers such as smooth muscle actin (SMA) and fibroblast activation protein (FAP), high expression of SMA in the peritumoral stroma has been reported to be a prognostic factor in various cancers. However, the effect of high FAP expression in intrahepatic cholangiocarcinoma (IHCC) has not been fully clarified. We evaluated the expression of CAF markers, focusing on FAP expression in the peripheral and intratumoral regions, to clarify the association with survival in patients with IHCC. The study cohort comprised 37 patients who underwent curative resection for IHCC. The FAP expressions were evaluated in the peripheral and intratumoral regions of the resected tissues. Clinicopathological factors and survival outcomes were investigated between patients with high versus low FAP expression. Uni- and multivariate analyses were performed to identify the prognostic factors for overall survival and relapse-free survival. The median area percentages of FAP expression in the peripheral and intratumoral regions were 15.5% and 17.8%, respectively. High FAP expression in the intratumoral region was significantly associated with worse overall survival and disease-free survival than low FAP expression in the intratumoral region. Multivariate analysis identified high intratumoral FAP expression as a risk factor for worse overall survival (hazard ratio, 2.450; p = 0.049) and relapse-free survival (hazard ratio, 2.743; p = 0.034). High intratumoral FAP expression was associated with worse survival, suggesting that intratumoral FAP expression represents malignant progression in patients with IHCC. (Keyword) Humans / Neoplasm Recurrence, Local / Cholangiocarcinoma / Cancer-Associated Fibroblasts / Bile Ducts, Intrahepatic / Bile Duct Neoplasms / Prognosis (Tokushima University Institutional Repository) ● Metadata: 119225 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12876-023-03012-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38017374 ● Search Scopus @ Elsevier (PMID): 38017374 ● Search Scopus @ Elsevier (DOI): 10.1186/s12876-023-03012-x (Tokushima University Institutional Repository: 119225, DOI: 10.1186/s12876-023-03012-x, PubMed: 38017374)
3.	Yuhei Waki, Yu Saitou, Shuhai Chen, Tetsuya Ikemoto, Takayuki Noma, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : Effects of green light-emitting diode irradiation on hepatic differentiation of hepatocyte-like cells generated from human adipose-derived mesenchymal cells., Scientific Reports, Vol.13, No.1, 19954, 2023. (Summary) Light-emitting diode (LED) irradiation has been used in the differentiation of mesenchymal stem cells into a variety of cell types. This study investigated the effect of green LED (GLED) irradiation on the differentiation of adipocyte-derived mesenchymal cells into hepatocyte-like cells (HLCs) and the mechanism of its action. HLCs in the hepatocyte maturation phase were irradiated with GLED (520 nm, 21 W/m, 5 min/day for 10 days). The cells were then assessed for expression of hepatocyte maturity genes and opsin 3 (OPN3), hepatocyte function, viability, apoptosis, and levels of reactive oxygen species (ROS), intracellular adenosine triphosphate (ATP) and calcium ions (Ca). GLED irradiation increased Alpha-1 antitrypsin and Ornithine transcarbamylase gene expression, promoted Cytochrome P450 3A4 activity and urea synthesis, and elevated intracellular ROS, ATP and Ca levels. OPN3 expression was significantly more upregulated in GLED-irradiated HLCs than in the non-irradiated HLCs. No significant difference in cell viability or apoptosis was observed between GLED-irradiated and non-irradiated HLCs. GLED irradiation can promote hepatocyte maturation and functions through OPN3. GLED irradiation also stimulated mitochondrial function via Ca/ATP/ROS activation. GLED irradiation has potential to support cell-based transplantation in patients. (Keyword) Humans / Reactive Oxygen Species / Hepatocytes / Cell Differentiation / Adipocytes / Adenosine Triphosphate / Rod Opsins (Tokushima University Institutional Repository) ● Metadata: 119238 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-023-45967-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37968291 ● Search Scopus @ Elsevier (PMID): 37968291 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-023-45967-7 (Tokushima University Institutional Repository: 119238, DOI: 10.1038/s41598-023-45967-7, PubMed: 37968291)
4.	Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Sonoko Yasui-Yamada, Maki Nishi, Hiroshi Sakaue, Motomu Kamada, Tetsuya Matsuura and Mitsuo Shimada : Preoperative Weight Loss Program for Hepatocellular Carcinoma Patients with High Body Mass Index in Hepatectomy., World Journal of Surgery, Vol.47, No.12, 3348-3355, 2023. (Summary) This study aimed to investigate the usefulness of a weight-loss program (WLP) in patients with a high body mass index (BMI) prior to liver resection (Hx) for hepatocellular carcinoma (HCC). Among 445 patients with HCC who underwent initial Hx between 2000 and 2020, 19 with a high BMI (≥25.0) were enrolled in our WLP since 2014. For calorie restriction, the amount of energy consumed was calculated as the standard body weight (SBW) kg × 20-25 kcal/day. Protein mass was calculated as SBW kg × 1.0-1.2 g/day to maintain skeletal muscle mass. Patients also performed both aerobic and resistance exercises. The before-and-after changes were compared, and the effect of WLP on the short- and long-term results was investigated. The average length of WLP was 21 days, and weight loss was successfully achieved in all patients. Body fat mass was reduced during the program, while skeletal muscle mass was maintained. WLP led to improvements in liver function and fibrotic markers, without tumor progression. There were no postoperative complications (≥Clavien-Dindo [CD] III). A retrospective comparison between with and without WLP using propensity score-matching analysis revealed that WLP group showed better NLR value, however, there were no significant differences in both short and long-term outcomes after Hx based on participation in the WLP. WLP with multidisciplinary intervention improved immune-nutrition status and liver function of obese patients. WLP had not affected both short and long-term outcomes after Hx. (Keyword) Humans / Carcinoma, Hepatocellular / Hepatectomy / Liver Neoplasms / Body Mass Index / Weight Reduction Programs / Retrospective Studies / Propensity Score / Treatment Outcome / Laparoscopy (Link to Publication Site) ● Publication site (DOI): 10.1007/s00268-023-07220-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37840060 ● Search Scopus @ Elsevier (PMID): 37840060 ● Search Scopus @ Elsevier (DOI): 10.1007/s00268-023-07220-0 (DOI: 10.1007/s00268-023-07220-0, PubMed: 37840060)
5.	仲須千春, Shin-ichiro Yamada, Hiroki Teraoku, Yu Saitou, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 原因が不明であった肝palisading granulomaの1例, Acta Hepatologica Japonica, Vol.64, No.10, 504-509, 2023. (Summary) 患者は50代女性.検診の腹部超音波検査で肝S3に16×14mm大の腫瘤を指摘され精査加療目的に当科紹介となった.既往歴・生肉食歴なし.術前の血液検査で異常なく,末梢好酸球も正常.造影CTの動脈・門脈相では辺縁に造影効果を認めるが,平衡相では造影されず,MRI T1強調像で低信号,T2強調像で低∼等信号,拡散強調像でやや高信号であった.PET-CTで肝臓への集積は認めなった.悪性腫瘍の可能性を完全に否定できず,腹腔鏡下肝部分切除を施行した.病理組織学的には腫瘤全体に凝固壊死像が見られ,辺縁に線維増生を伴い,組織球が柵状に配列したpalisading granulomaであった.原因特定のために複数の染色を行ったが,病原体は同定できなかった.palisading granulomaは術前診断が困難であり,診断的治療として腹腔鏡下肝切除術は有用であると考えられた.(著者抄録) (Keyword) 肝切除肝臓疾患(病理学,画像診断,外科的療法) 超音波診断肉芽腫-好酸球性(病理学,画像診断,外科的療法) 腹腔鏡法幼虫移行症-内臓拡散MRI PET-CT検査ヒト中年(45∼64) 女 (Link to Publication Site) ● Publication site (DOI): 10.2957/kanzo.64.504 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.2957/kanzo.64.504 (DOI: 10.2957/kanzo.64.504)
6.	Kouzou Yoshikawa, Mitsuo Shimada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and Shoichiro Takao : Clinical impact of myosteatosis measured by magnetic resonance imaging on long-term outcomes of hepatocellular carcinoma after radical hepatectomy., BMC Surgery, Vol.23, No.1, 281, 2023. (Summary) A variety of factors have been reported to affect long-term outcomes after radical resection of hepatocellular carcinoma (HCC). However, the indicators remain controversial. The purpose of this study was to evaluate the relationship between myosteatosis of the multifidus muscle and long-term outcomes after radical surgery for HCC. We retrospectively analyzed clinicopathological data for 187 patients with HCC who underwent radical surgery at Tokushima University between January 2009 and December 2020 and measured the density of fat in the multifidus muscle at L3 on their preoperative magnetic resonance images (MRI). Associations of myosteatosis and clinicopathological factors with long-term outcomes were evaluated. The patients were divided into a myosteatosis-negative group (n = 122) and a myosteatosis-positive group (n = 65). The cancer-specific survival rate after hepatectomy was significantly worse in the myosteatosis-positive group than in the myosteatosis-negative group (p = 0.03). Univariate analysis identified multiple tumors, stage III/IV disease, an alfa-fetoprotein level ≥ 10 ng/ml, PIVKA-II ≥ 400 AU/ml, vp(+) status, and myosteatosis to be prognostic factors for cancer-specific survival. Multivariate analysis revealed multiple tumors, an alfa-fetoprotein level ≥ 10 ng/ml, and myosteatosis to be independent prognostic factors. Myosteatosis measured by MRI is a simple and useful predictor of the long-term outcome after radical surgery for HCC. (Keyword) Humans / Carcinoma, Hepatocellular / Hepatectomy / Retrospective Studies / Liver Neoplasms / Magnetic Resonance Imaging / Fetal Proteins (Tokushima University Institutional Repository) ● Metadata: 119226 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12893-023-02188-z (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37715229 ● Search Scopus @ Elsevier (PMID): 37715229 ● Search Scopus @ Elsevier (DOI): 10.1186/s12893-023-02188-z (Tokushima University Institutional Repository: 119226, DOI: 10.1186/s12893-023-02188-z, PubMed: 37715229)
7.	Shuhai Chen, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : TU-100 Antagonizes the M2 Polarization Phenotype of Macrophages in the Tumor Microenvironment by Suppressing the TLR4/NF-B/STAT3 Axis., Anticancer Research, Vol.43, No.5, 1985-1992, 2023. (Summary) Macrophages are the most abundant immune cells in the tumor stroma, and their polarization states within the tumor microenvironment (TME) exert critical roles in tumorigenesis. TU-100 (Daikenchuto) is a commonly prescribed Japanese herbal medicine that has shown anti-cancer effects by regulating cancer-associated fibroblasts (CAFs) in the TME. However, its effects on tumor-associated macrophages (TAMs) remain unclear. TAMs were generated by macrophage exposure to tumor-conditioned medium (CM), and their polarization states were evaluated after TU-100 treatment. The underlying mechanism was further studied. TU-100 exhibited little cytotoxicity over a range of doses in M0 macrophages and TAMs. However, it could antagonize the M2-like polarization of macrophages evoked by tumor-CM exposure. These effects might be caused by the inhibition of TLR4/NF-B/STAT3 signaling in the M2-like phenotype of macrophages. Interestingly, TU-100 antagonized the malignancy promoting effects of M2 macrophages on hepatocellular carcinoma cell lines in vitro. Mechanistically, the administration of TU-100 restrained the high expression of MMP-2, COX-2, and VEGF in TAMs. TU-100 may alleviate the progression of cancer by regulating the M2 polarization of macrophages within the TME, suggesting a viable therapeutic approach. (Keyword) Humans / Cell Line, Tumor / Cell Polarity / Macrophages / Naphthoquinones / NF-kappa B / Signal Transduction / Tumor Microenvironment / Antineoplastic Agents, Phytogenic / Carcinoma, Hepatocellular (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.16359 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37097685 ● Search Scopus @ Elsevier (PMID): 37097685 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.16359 (DOI: 10.21873/anticanres.16359, PubMed: 37097685)
8.	Takayuki Noma, Hiroki Teraoku, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 術前に肝細胞癌との鑑別が困難であった筋腫型肝血管筋脂肪腫の1例, Acta Hepatologica Japonica, Vol.64, No.4, 201-208, 2023. (Summary) 患者は40代女性.検診で肝から突出する15cmの巨大腫瘤を指摘され,精査加療目的に当科紹介となった.既往歴や背景肝に特記事項なく,腫瘍マーカーは正常であったが,造影CTの動脈・門脈相で肝右葉に15cm大の早期濃染と遅延相でwashoutを認めた.EOB-MRI肝細胞相ではdefectとして描出され肝細胞癌が疑われた.破裂の危険性を考慮し,まずTACEを行い,その後拡大肝右葉切除を施行した.病理組織学的には腫瘍の大半が平滑筋様細胞で構成されており,脂肪細胞は認めず,免疫組織化学染色にてVimentin,αSMA,HMB-45,melan Aが陽性であり,Perivascular epithelioid cell tumor(PEComa)として包括される腫瘍群の中の筋腫型の肝血管筋脂肪腫(Angiomyolipoma;AML)と診断した.今回我々は,術前に肝細胞癌との鑑別が困難であった,若年女性に発生した肝原発筋腫型AMLを経験したため報告する.(著者抄録) (Keyword) 肝細胞癌肝切除肝臓腫瘍(画像診断,病理学,外科的療法) 筋腫(画像診断,病理学,外科的療法) 鑑別診断術前評価超音波診断 X線CT 免疫組織化学 *血管筋脂肪腫(画像診断,病理学,外科的療法) 拡散MRI 腹部CT ヒト女 (Link to Publication Site) ● Publication site (DOI): 10.2957/kanzo.64.201 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.2957/kanzo.64.201 (DOI: 10.2957/kanzo.64.201)
9.	Katsuki Miyazaki, Yuji Morine, Caiming Xu, Chiharu Nakasu, Yuuma Wada, Hiroki Teraoku, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Mitsuo Shimada and Ajay Goel : Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma., Cells, Vol.12, No.4, 612, 2023. (Summary) Lenvatinib is a multi-kinase inhibitor approved as a first-line treatment for patients with unresectable advanced hepatocellular carcinoma (HCC). However, its response rate is unsatisfactory, primarily due to the acquisition of resistance, which limits its clinical significance for treating patients with HCC. Recent evidence suggests that epidermal growth factor receptor (EGFR) activation can trigger Lenvatinib-resistance; and is considered an important therapeutic target in HCC. Curcumin, one of the most studied naturally occurring botanicals with robust anti-cancer activity, is also reported to be a potent tyrosine kinase inhibitor. In this study, we hypothesized that the anti-EGFR potential of Curcumin might help overcome Lenvatinib resistance in HCC. We established two Lenvatinib-resistant cells and discovered that a combination of Curcumin and Lenvatinib exhibited a synergistic anti-tumor efficacy in the resistant HCC cell lines. In line with previous reports, Lenvatinib-resistant cell lines revealed significant activation of the EGFR, and genomewide transcriptomic profiling analysis identified that the PI3K-AKT pathway was associated with Lenvatinib resistance. The combination treatment with Curcumin and Lenvatinib dramatically suppressed gene and protein expression of the EGFR-PI3K-AKT pathway, suggesting Curcumin overcomes Lenvatinib resistance via inhibition of EGFR. We further validated these findings in tumor spheroids derived from resistant cell lines. In conclusion, we, for the first time, report that Curcumin reverses Lenvatinib resistance in HCC, and that their combination has clinical application potential for adjunctive treatment in HCC. (Keyword) Humans / Carcinoma, Hepatocellular / Curcumin / Liver Neoplasms / Proto-Oncogene Proteins c-akt / Phosphatidylinositol 3-Kinases / Cell Line, Tumor / Signal Transduction / Protein Kinase Inhibitors / ErbB Receptors (Tokushima University Institutional Repository) ● Metadata: 118580 (Link to Publication Site) ● Publication site (DOI): 10.3390/cells12040612 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36831279 ● Search Scopus @ Elsevier (PMID): 36831279 ● Search Scopus @ Elsevier (DOI): 10.3390/cells12040612 (Tokushima University Institutional Repository: 118580, DOI: 10.3390/cells12040612, PubMed: 36831279)
10.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Yuhei Waki, Takayuki Noma, Tetsuya Ikemoto and Mitsuo Shimada : Multiplication of tumor maximum diameter and number as a new surgical indicator for Barcelona Clinic Liver Cancer intermediate-stage hepatocellular carcinoma., Hepatology Research, Vol.53, No.6, 531-539, 2023. (Summary) Recent advances in treatment modalities have been made, limiting the indication of hepatic resection in the treatment strategy for hepatocellular carcinoma (HCC) patients. This retrospective study investigated the significance of multiplication of tumor maximum diameter and number (MDN) as a surgical indicator for Barcelona Clinic Liver Cancer intermediate-stage HCC. A total of 49 patients with Barcelona Clinic Liver Cancer intermediate-stage HCC who underwent curative hepatic resection between 2000 and 2020 were enrolled in this study. Prognostic factors of overall survival and disease-free survival, including the product of MDN, were analyzed. Patients with MDN >12 experienced significantly worse prognosis compared with those with MDN ≤12 (p = 0.0395), and 5-year overall survival rates after hepatic resection were 60.0% and 23.4%, respectively. Furthermore, the disease-free survival rate of patients with MDN >12 was significantly worse compared with those with MDN ≤12 (p = 0.0049), and all patients with MDN >12 experienced recurrence within 3 years after hepatic resection. In the multivariate analysis, MDN >12 was identified as the only independent prognostic factor of both overall survival and disease-free survival. In addition, patients with MDN >12 suffered from uncontrollable recurrence by locoregional treatment, such as more than four intrahepatic and extrahepatic recurrences, after hepatic resection. MDN index might be a new surgical indicator for Barcelona Clinic Liver Cancer intermediate-stage HCC, and influence clinical decision-making for individual treatment strategies. (Link to Publication Site) ● Publication site (DOI): 10.1111/hepr.13887 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36755370 ● Search Scopus @ Elsevier (PMID): 36755370 ● Search Scopus @ Elsevier (DOI): 10.1111/hepr.13887 (DOI: 10.1111/hepr.13887, PubMed: 36755370)
11.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Yuhei Waki, Chiharu Nakasu and Mitsuo Shimada : Impact of apparent diffusion coefficient on prognosis of early hepatocellular carcinoma: a case control study., BMC Surgery, Vol.23, No.1, 6, 2023. (Summary) We investigated the usefulness of apparent diffusion coefficients (ADC) from diffusion-weighted images (DWI) obtained using magnetic resonance imaging (MRI) for prognosis of early hepatocellular carcinoma (HCC): Barcelona Clinic Liver Cancer (BCLC) stage 0 and A. We enrolled 102 patients who had undergone surgical resection for early HCC: BCLC stage 0 and A, and calculated their minimum ADC using DWI-MRI. We divided patients into ADC (n = 72) and ADC (n = 30) groups, and compared clinicopathological factors between the two groups. The ADC group showed higher protein induced by vitamin K absence-II (PIVKA-II) levels (p = 0.02) compared with the ADC group. In overall survival, the ADC group showed significantly worse prognosis than the ADC group (p < 0.01). Univariate analysis identified multiple tumors, infiltrative growth, high PIVKA-II, and low ADC value as prognostic factors. Multivariate analysis identified infiltrative growth and low ADC value as an independent prognostic factor. ADC values can be used to estimate the prognosis of early HCC. (Keyword) Humans / Carcinoma, Hepatocellular / Liver Neoplasms / Case-Control Studies / Retrospective Studies / Prognosis (Tokushima University Institutional Repository) ● Metadata: 118558 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12893-022-01892-6 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36631851 ● Search Scopus @ Elsevier (PMID): 36631851 ● Search Scopus @ Elsevier (DOI): 10.1186/s12893-022-01892-6 (Tokushima University Institutional Repository: 118558, DOI: 10.1186/s12893-022-01892-6, PubMed: 36631851)
12.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : Fontan associated liver disease(FALD)関連肝癌に対しての腹腔鏡肝切除の1例 Fontan循環における肝離断対策, Acta Hepatologica Japonica, Vol.64, No.1, 18-25, 2023. (Summary) 30代男性,3歳時に単心房・単心室症を背景にFontan手術を受けた.Fontan associated liver disease(FALD)として肝臓内科にフォローを開始されて以来3年後にFALD関連肝癌を疑われ,腹腔鏡肝切除を施行した.肝離断中は,Central venous pressure(CVP)圧を下げるため,positive end expiratory pressureをオフし,最小限の輸液量,利尿剤併用しながらの麻酔管理を行うも,Fontan循環の影響でCVPコントロールは不良で,静脈性出血が継続したままの肝離断となった.本症例は,術後合併症なく経過したものの,FALD関連肝癌症例は,Fontan循環による高CVP下での肝離断を余儀なくされるため,そのジレンマを解決する必要があり,その対策に関して考察を加え報告する.(著者抄録) (Keyword) 肝細胞癌(画像診断,病理学,外科的療法) 肝切除肝内胆管(画像診断,病理学,外科的療法) 超音波診断胆管癌(画像診断,病理学,外科的療法) 胆管腫瘍(画像診断,病理学,外科的療法) X線CT 中心静脈圧 *腹腔鏡法免疫組織化学複合腫瘍と混合腫瘍(画像診断,病理学,外科的療法) 超音波外科拡散MRI 腹部CT ヒト成人(19∼44) 男 (Link to Publication Site) ● Publication site (DOI): 10.2957/kanzo.64.18 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.2957/kanzo.64.18 (DOI: 10.2957/kanzo.64.18)
13.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki, Shohei Okikawa, Katsuki Miyazaki, Chiharu Nakasu, Takayuki Noma, Akira Takahashi and Mitsuo Shimada : Impact of pancreatic resection in patients with liver cirrhosis., The Journal of Medical Investigation : JMI, Vol.70, No.1.2, 189-194, 2023. (Summary) Several reports have shown a high mortality rate in patients with liver cirrhosis (LC) who undergo pancreaticoduodenectomy, however, there are few reports on its long-term prognosis. Twelve patients with LC who had undergone pancreatic resection were enrolled. To compare clinicopathological variables, 159 non-LC patients who had undergone resection for pancreatic cancer were enrolled. Pancreaticoduodenectomy (PD) was performed in 5 LC patients and distal pancreatectomy (DP) was performed in 7 LC patients. Patients in the LC group had more co-morbidities, lower platelet counts and higher Fib4 index than the non-LC group. The postoperative complication rate was higher in the LC group (83.3% vs 47.8%). While the postoperative hospital stay and 30-day mortality rate were not different, the 90-day mortality rate was higher in the LC group (25.0% vs 2.5% ; p<0.01). Comparison by operative procedure showed no significant differences of postoperative outcomes in DP cases. However, in PD cases, postoperative complications were more frequent (100% vs 42.3%) and 90-day mortality was higher (40.0% vs 2.9% ; p<0.01) in the LC group. PD resulted in higher postoperative morbidity and mortality rates in patients with LC compared with non-LC patients. DP could be tolerated in the LC patients. J. Med. Invest. 70 : 189-194, February, 2023. (Keyword) Humans / Pancreatectomy / Treatment Outcome / Retrospective Studies / Pancreaticoduodenectomy / Pancreatic Neoplasms / Postoperative Complications / Liver Cirrhosis (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.70.189 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37164719 ● Search Scopus @ Elsevier (PMID): 37164719 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.189 (DOI: 10.2152/jmi.70.189, PubMed: 37164719)
14.	Baasansuren Selenge, Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Chie Takasu, Hiroki Teraoku, Shohei Okikawa and Mitsuo Shimada : Impact of L-type amino acid transporter 1 on intrahepatic cholangiocarcinoma., The Journal of Medical Investigation : JMI, Vol.70, No.1.2, 160-165, 2023. (Summary) Amino acid transporters, such as L-type amino acid transporter 1 (LAT1), have an effect on tumor growth, metastasis, and survival of various solid tumors. However, the role of LAT1 in patients with intrahepatic cholangiocarcinoma (IHCC) remains unknown. Forty-six patients who had undergone initial hepatic resection for IHCC at Tokushima University Hospital were enrolled in this study. Immunohistochemical analysis of LAT1 and phosphorylated Akt (p-AKT) was performed using resected specimens. Clinicopathological factors, including prognosis, were analyzed between LAT1-high and LAT1-low groups. The LAT1-high group showed a higher proportion of periductal infiltrating type and higher carcinoembryonic antigen/carbohydrate antigen 19-9 levels compared with the LAT1-low group. Multivariate analysis revealed that LAT1-high expression was an independent prognostic factor for disease-free survival. Furthermore, the proportion of p-AKT positivity was higher in the LAT1-high group than in the LAT1-low group. LAT1 expression was associated with poor prognosis of IHCC and higher p-Akt expression. J. Med. Invest. 70 : 160-165, February, 2023. (Keyword) Humans / Bile Duct Neoplasms / Bile Ducts, Intrahepatic / Biomarkers, Tumor / Cholangiocarcinoma / Prognosis / Proto-Oncogene Proteins c-akt (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.70.160 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37164714 ● Search Scopus @ Elsevier (PMID): 37164714 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.160 (DOI: 10.2152/jmi.70.160, PubMed: 37164714)
15.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Shohei Okikawa, Katsuki Miyazaki and Mitsuo Shimada : Short- and long-term outcomes of pancreatectomy in patients with hemodialysis., The Journal of Medical Investigation : JMI, Vol.70, No.1.2, 105-109, 2023. (Summary) Several reports have shown the high mortality rate of pancreatic resection in patients with hemodialysis (HD), however, its long-term outcome remains unclear. In this study, we examined cases of pancreatic resection in patients with HD and conducted a literature review. Four patients with HD who underwent pancreatic resection from 2004 to 2019 were enrolled. To compare the clinicopathological variables of HD and non-HD patients, 161 non-HD patients who had undergone surgical resection for pancreatic cancer were enrolled. Among four cases of pancreatic resection with HD, three cases were malignant diseases. All patients with HD had some co-morbidities (100% in HD group, 45.3% in the non-HD group) and postoperative complications (100% in the HD group, vs 46.6% in the non-HD group). Although one patient had severe postoperative complications and length of postoperative hospital stay was longer, the 30- and 90-day mortality rates were both 0% in patients with HD. However, three cases in the HD group (75%) died approximately 6 months after surgery, including one cancer-related death. Pancreatic surgery in patients with HD should be carefully indicated, especially pancreaticoduodenectomy or total pancreatectomy, because of the poor prognosis induced by non-cancer-related causes of death. J. Med. Invest. 70 : 105-109, February, 2023. (Keyword) Humans / Pancreatectomy / Pancreatic Neoplasms / Pancreaticoduodenectomy / Postoperative Complications / Retrospective Studies (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.70.105 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37164704 ● Search Scopus @ Elsevier (PMID): 37164704 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.105 (DOI: 10.2152/jmi.70.105, PubMed: 37164704)
16.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 【胆膵疾患と最新テクノロジーの融合】胆膵疾患における最新の術前術中手術支援システム, Journal of Biliary Tract & Pancreas, Vol.43, No.12, 1631-1636, 2022. (Summary) 胆膵手術における術前シミュレーションは,腫瘍進展範囲あるいは主要脈管解剖をいかに正確にイメージできるかが,ポイントとなる．空間認識力という意味で,extended realityは有用である．また,術中ナビゲーションに関しては,ICG蛍光法がゴールドスタンダードとなるが,人工知能を駆使した最新の知見,ならびに自験例も踏まえて,本稿で紹介する．(著者抄録) (Keyword) Indocyanine Green(診断的利用) 術中モニタリング人工知能膵臓疾患(X線診断,外科的療法) 膵頭十二指腸切除ソフトウェア X線CT 胆道疾患(X線診断,外科的療法) DICOM 蛍光血管撮影シミュレーション訓練手術ナビゲーションシステム胆管切除術ヒト
17.	Baasansvren Selenge, Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Chie Takasu, Hiroki Teraoku and Mitsuo Shimada : Impact of L-type amino acid transporter 3 on the prognosis of hepatocellular carcinoma., Oncology Letters, Vol.24, No.5, 418, 2022. (Summary) The aim of the present study was to investigate the impact of L-type amino acid transporter 3 (LAT3) expression on the prognosis of hepatocellular carcinoma (HCC). A total of 135 patients who had undergone initial hepatic resection for HCC at Tokushima University Hospital (Tokushima, Japan) were enrolled in the present study. Immunohistochemical analysis of LAT3 and phosphorylated AKT (p-AKT) was performed using resected specimens. Clinicopathological factors, including prognosis, were compared between the LAT3-high and -low expression groups. The results demonstrated that the LAT3-high group showed significantly higher protein induced by vitamin K absence-II levels (P=0.01) compared with the LAT3-low group. The LAT3-high group showed significantly worse prognosis compared with the LAT3-low group regarding cancer-specific survival and disease-free survival (P<0.05). Multivariate analysis revealed that high LAT3 expression and multiple tumors were independent prognostic factors for cancer-specific survival. Furthermore, the rate of p-AKT-positive cases was higher in the LAT3-high group than in the LAT3-low group. Overall, these findings suggested that LAT3 expression was associated with poor prognosis of HCC and high p-AKT expression. (Tokushima University Institutional Repository) ● Metadata: 118271 (Link to Publication Site) ● Publication site (DOI): 10.3892/ol.2022.13538 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36245821 ● Search Scopus @ Elsevier (PMID): 36245821 ● Search Scopus @ Elsevier (DOI): 10.3892/ol.2022.13538 (Tokushima University Institutional Repository: 118271, DOI: 10.3892/ol.2022.13538, PubMed: 36245821)
18.	Shohei Okikawa, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Hiroki Teraoku, Katsuki Miyazaki, Shoko Yamashita, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : Inhibition of the VEGF signaling pathway attenuates tumor-associated macrophage activity in liver cancer., Oncology Reports, Vol.47, No.4, 2022. (Summary) Tumor-associated macrophage (TAMs) are paramount for tumor progression and immune tolerance in the tumor microenvironment of various types of cancer, including liver cancer. The aim of the present study was to investigate the effect of vascular endothelial growth factor (VEGF) inhibition on TAM polarization and function during their interactions with macrophages and liver cancer cells. TAMs were induced by culturing M0 macrophages with cancer cell-conditioned medium. TAMs cultured with cancer cell-conditioned medium and vascular endothelial growth factor (VEGF) inhibitor were defined as modified TAMs, and the expression levels of TAM-associated markers and VEGF receptor 2 were evaluated using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The effects of TAMs and modified TAMs on cancer cell proliferation and migration were investigated using conditioned medium. Programmed death-ligand 1 (PD-L1) mRNA expression in modified TAMs and cancer cells cultured in modified TAM-conditioned medium (TAM-CM) for 48 h was examined using RT-qPCR. In order to investigate signaling pathways in macrophages, western blot analysis was performed. CD163 and CD206 and M2 macrophage marker expression was upregulated in TAMs and modified TAMs. Modified TAM-CM exhibited a decreased ability to promote cancer cell proliferation and migration in comparison with the use of TAM-CM. The VEGF concentration was significantly higher in the TAMs than in M0 macrophages; however, the modified TAMs displayed a significantly lower VEGF secretion than TAMs. PD-L1 expression was decreased in modified TAMs as compared with TAMs. Western blot analysis revealed that the Akt/mTOR signaling pathway was significantly suppressed in the modified TAMs compared with TAMs. It was observed that TAMs cultured in a VEGF-depleted environment displayed lower secretion levels of cytokines involved in tumor progression and a decreased immune tolerance-inducing ability. On the whole, the results of the present study suggested that VEGF inhibition in TAMs may be a potential therapeutic target for liver cancer. (Keyword) Cell Line, Tumor / Humans / Liver Neoplasms / Signal Transduction / Tumor Microenvironment / Tumor-Associated Macrophages / Vascular Endothelial Growth Factor A (Tokushima University Institutional Repository) ● Metadata: 118964 (Link to Publication Site) ● Publication site (DOI): 10.3892/or.2022.8282 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35169858 ● Search Scopus @ Elsevier (PMID): 35169858 ● Search Scopus @ Elsevier (DOI): 10.3892/or.2022.8282 (Tokushima University Institutional Repository: 118964, DOI: 10.3892/or.2022.8282, PubMed: 35169858)
19.	Hiroki Teraoku, Yuji Morine, Naoto Uyama, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Satoru Imura, Masafumi Harada and Mitsuo Shimada : Role of Central Hypo-enhancement in the Hepatic Arterial Phase of Dynamic Computed Tomography in Patients with Mass-Forming Intrahepatic Cholangiocarcinoma., World Journal of Surgery, Vol.44, No.7, 2350-2358, 2020. (Summary) The enhancement pattern in the hepatic arterial phase (HAP) of dynamic computed tomography (CT) is reportedly a prognostic marker in patients with intrahepatic cholangiocarcinoma (IHCC). This study was performed to clarify the significance of central hypo-enhancement in the HAP in patients with mass-forming IHCC. Forty patients who had undergone initial surgical resection for mass-forming IHCC were enrolled. The dynamic CT was scanned 40 s after contrast agent injection as the HAP. A radiologist classified the patients into three groups based on the vascular pattern: the hyper-enhancement group (Hyper group), rim-enhancement group (Rim group), and hypo-enhancement group (Hypo group). The surgical specimens were immunohistochemically stained for hypoxia-inducible factor 1 (HIF-1). The correlation with clinicopathological findings and HIF-1 expression was investigated. The Hyper, Rim, and Hypo groups comprised 8, 7, and 25 patients, respectively. There were no significant correlations between the groups and clinicopathological factors. Overall survival (OS) was significantly worse in the Hypo than in the Hyper group (p = 0.03). OS was also significantly worse in the Rim +ypo group (i.e., hypo-enhancement in the central tumor) than in the Hyper group (p = 0.04). Furthermore, inclusion in the Rim +ypo group was a prognostic factor for OS (hazard ratio 6.68). High HIF-1 expression in the central part of the tumor was correlated with central hypo-enhancement (Hyper group: 25% and Rim +ypo group: 72%). Central hypo-enhancement was a prognostic factor in patients with IHCC. The high malignant potential of tumors with central hypo-enhancement might be associated with HIF-1 upregulation. (Keyword) Adult / Aged / Bile Duct Neoplasms / Bile Ducts, Intrahepatic / Biomarkers, Tumor / Cholangiocarcinoma / Contrast Media / Female / Follow-Up Studies / Hepatectomy / Hepatic Artery / Humans / Hypoxia-Inducible Factor 1, alpha Subunit / Male / Middle Aged / Multidetector Computed Tomography / Prognosis / Proportional Hazards Models / Retrospective Studies (Link to Publication Site) ● Publication site (DOI): 10.1007/s00268-020-05456-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32152739 ● Search Scopus @ Elsevier (PMID): 32152739 ● Search Scopus @ Elsevier (DOI): 10.1007/s00268-020-05456-8 (DOI: 10.1007/s00268-020-05456-8, PubMed: 32152739)
20.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Chie Takasu, Masato Yoshikawa, Hiroki Teraoku and Toshiaki Yoshimoto : A new formula to calculate the resection limit in hepatectomy based on Gd-EOB-DTPA-enhanced magnetic resonance imaging., PLoS ONE, Vol.14, No.1, e0210579, 2019. (Summary) Dynamic magnetic resonance imaging with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (EOB-MRI) can be used not only to detect liver tumors but also to estimate liver function. The aim of this study was to establish a new EOB-MRI-based formula to determine the resection limit in patients undergoing hepatectomy. Twenty-eight patients with a normal liver (NL group) and five with an unresectable cirrhotic liver (UL group) who underwent EOB-MRI were included. Standardized liver function (SLF) was calculated based on the signal intensity (SI), the volume of each subsegment (S1-S8), and body surface area. A formula defining the resection limit was devised based on the difference in the SLF values of patients in the NL and UL groups. The formula was validated in 50 patients who underwent EOB-MRI and hepatectomy. The average SLF value in the NL and UL groups was 2038 and 962 FV/m2, respectively. The difference (1076 FV/m2) was consistent with a 70% in resection volume. Thus, the resection limit for hepatectomy was calculated as a proportion of 70%: 70 (SLF-962)/1076 (%). The one patient who underwent hepatectomy over the resection limit died due to liver failure. In other 49 patients, in whom the resection volume was less than the resection limit, procedures were safely performed. Our formula for resection limit based on EOB-MRI can improve the safety of hepatectomy. (Tokushima University Institutional Repository) ● Metadata: 113041 (Link to Publication Site) ● Publication site (DOI): 10.1371/journal.pone.0210579 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30682046 ● Search Scopus @ Elsevier (PMID): 30682046 ● Search Scopus @ Elsevier (DOI): 10.1371/journal.pone.0210579 (Tokushima University Institutional Repository: 113041, DOI: 10.1371/journal.pone.0210579, PubMed: 30682046)
21.	Toshiaki Yoshimoto, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Daichi Ishikawa, Hiroki Teraoku, Masato Yoshikawa, Jun Higashijima, Chie Takasu and Mitsuo Shimada : Maximum Diameter and Number of Tumors as a New Prognostic Indicator of Colorectal Liver Metastases., In Vivo, Vol.31, No.3, 419-423, 2017. (Summary) Surgical resection is currently considered the only potentially curative option as a treatment strategy of colorectal liver metastases (CRLM). However, the criteria for selection of resectable CRLM are not clear. The aim of this study was to confirm a new prognostic indicator of CRLM after hepatic resection. One hundred thirty nine patients who underwent initial surgical resection from 1994 to 2015 were investigated retrospectively. Prognostic factors of overall survival including the product of maximum diameter and number of metastases (MDN) were analyzed. Primary tumor differentiation, vessel invasion, lymph node (LN) metastasis, non-optimally resectable metastases, H score, grade of liver metastases, resection with non-curative intent and MDN were found to be prognostic factors of overall survival (OS). In multivariate analyses of clinicopathological features associated with OS, MDN and non-curative intent were independent prognostic factors. Patients with MDN ·30 had shown significantly poorer prognosis than patients with MDN <30 in OS and relapse-free survival (RFS). MDN ·30 is an independent prognostic factor of survival in patients with CRLM and optimal surgical criterion of hepatectomy for CRLM. (Keyword) Adult / Aged / Aged, 80 and over / Cell Differentiation / Colorectal Neoplasms / Female / Follow-Up Studies / Hepatectomy / Humans / Liver Neoplasms / Lymphatic Metastasis / Male / Middle Aged / Multivariate Analysis / Prognosis / Retrospective Studies (Link to Publication Site) ● Publication site (DOI): 10.21873/invivo.11076 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28438872 ● Search Scopus @ Elsevier (PMID): 28438872 ● Search Scopus @ Elsevier (DOI): 10.21873/invivo.11076 (DOI: 10.21873/invivo.11076, PubMed: 28438872)
22.	Masato Yoshikawa, Yuji Morine, Tetsuya Ikemoto, Satoru Imura, Jun Higashijima, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Daichi Ishikawa, Hiroki Teraoku, Atsushi Takata, Toshiaki Yoshimoto and Mitsuo Shimada : Elevated Preoperative Serum CEA Level Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma Through the Epithelial-Mesenchymal Transition., Anticancer Research, Vol.37, No.3, 1169-1175, 2017. (Summary) Serum carcinoembryonic antigen (CEA) is used as an indicator of tumor progression in a variety of carcinomas. A subset of patients with hepatocellular carcinoma (HCC) exhibit increased serum CEA level, but the significance of this is unclear. In this study, we investigated the prognosis of patients with HCC with increased serum CEA, and explored the correlations with expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) and epithelial-mesenchymal transition (EMT) and tumor angiogenesis. One hundred and twenty-three patients with HCC who underwent radical resection were divided into two groups according to a cut-off value of 5.0 ng/ml for serum CEA: high (n=24) and normal (n=99) groups. We compared the clinicopathological factors with serum CEA levels and its correlations with CEACAM1 expression, EMT-related factors and microvessel density (MVD) of tumor tissues by immunohistochemistry. In the high CEA group, the disease-free survival (DFS) rate was significantly worse than in the normal CEA group. Multivariate analysis revealed that a high CEA level was an independent factor predictive of recurrence. Furthermore, increased serum CEA levels were positively correlated with CEACAM1 expression. Moreover, CEACAM1 expression was positively correlated with expression of EMT-related factors and MVD of tumor tissues. Increased serum CEA level reflected CEACAM1 expression and was an independent factor predictive of recurrence in HCC through EMT and tumor angiogenesis. (Keyword) Adult / Aged / Aged, 80 and over / Antigens, CD / Antigens, CD34 / Cadherins / Carcinoembryonic Antigen / Carcinoma, Hepatocellular / Cell Adhesion Molecules / Disease-Free Survival / Epithelial-Mesenchymal Transition / Female / Follow-Up Studies / Humans / Immunohistochemistry / Liver Neoplasms / Male / Microcirculation / Middle Aged / Neovascularization, Pathologic / Predictive Value of Tests / Preoperative Period / Prognosis / Recurrence / Vimentin (Tokushima University Institutional Repository) ● Metadata: 112034 (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.11430 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28314278 ● Search Scopus @ Elsevier (PMID): 28314278 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.11430 (Tokushima University Institutional Repository: 112034, DOI: 10.21873/anticanres.11430, PubMed: 28314278)
23.	M Davaadorj, Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Satoru Imura, Chie Takasu, Shin-ichiro Yamada, Hiroki Teraoku, Masato Yoshikawa and Mitsuo Shimada : Loss of Secreted Frizzled-Related Protein-1 expression is associated with poor prognosis in intrahepatic cholangiocarcinoma., EJSO - European Journal of Surgical Oncology, Vol.43, No.2, 344-350, 2017. (Summary) Secreted Frizzled-Related Protein-1 (SFRP1) is a well-known negative regulator of the wingless type (Wnt)- -catenin pathway and its inactivation plays an important role in the development and progression of many cancers. In this study, we aimed to determine the clinical significance of SFRP1 expression in intrahepatic cholangiocarcinoma (IHCC) and to define the relationship to Wnt- -catenin pathway. Fifty IHCC patients who had liver resection were enrolled in this study. SFRP1 protein expression was examined by immunohistochemistry in tumor tissues. The patients were divided into two groups: SFRP1 positive (n = 30) and negative (n = 20). Clinicopathological characteristics were analyzed. SFRP1 significantly correlated with curability (Cur A, B vs. C, p = 0.029); and recurrent pattern (intrahepatic vs. extrahepatic, p = 0.010). The negative SFRP1 group had significantly poorer prognosis, and 5-year survival rates were 8.1% of the negative SFRP1 group and 44.6% of the positive SFRP1 group, respectively. Moreover, the disease-free survival rate in the negative SFRP1 group was significantly poorer (p < 0.001). Multivariate analysis revealed that loss of SFRP1served as an independent prognostic factor in IHCC for both overall (HR, 2.923; 95% CI, 1.30-6.56; p = 0.009) and disease-free (HR, 2.631; 95% CI, 1.31-5.27; p = 0.006) survival. In addition, SFRP1 expression negatively correlated to -catenin expression (p = 0.005). Those results suggested that the loss of SFRP1 could be a poor prognostic factor for IHCC, through the Wnt- -catenin pathway. (Keyword) Aged / Biomarkers, Tumor / Cholangiocarcinoma / Female / Hepatectomy / Humans / Immunohistochemistry / Japan / Liver Neoplasms / Male / Prognosis / Proteins / Survival Rate (Tokushima University Institutional Repository) ● Metadata: 110034 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ejso.2016.11.017 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28062160 ● Search Scopus @ Elsevier (PMID): 28062160 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ejso.2016.11.017 (Tokushima University Institutional Repository: 110034, DOI: 10.1016/j.ejso.2016.11.017, PubMed: 28062160)

Review, Commentary:

1.	Shuichi Iwahashi, Hiroki Teraoku, Yu Saitou, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 【どこをどう切る?どうつなぐ?なぞって覚える!消化器外科術式理解イラストノート】肝臓・胆道の手術肝切除術, Gastroenterological Surgery Nursing, Vol.22, No.8, 704-708, Oct. 2017.
2.	Shin-ichiro Yamada, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Chie Takasu, Masato Yoshikawa, Hiroki Teraoku, Toshiaki Yoshimoto and Atsushi Takata : Effective stepwise training and procedure standardization for young surgeons to perform laparoscopic left hepatectomy., Surgical Endoscopy, Vol.31, No.6, 2623-2629, Dec. 2016. (Summary) Laparoscopic hepatectomy remains one of the most difficult procedures for young surgeons to perform. We recently developed a new training method and standardization procedure for teaching young surgeons to perform laparoscopic left hepatectomy (Lap-LHx). The aim of this study was to assess the effectiveness of our method. In 2004, we standardized a laparoscopic procedure for Lap-LHx, using a laparoscopy-assisted method as a stepping stone. The laparoscopic training method comprised the following three steps: (1) training in fundamental procedures using a dry box and checking by mentors; (2) detailed preoperative simulation using Vincent three-dimensional software for each patient; and (3) self-assessment including understanding of relevant anatomy and completion grade for each procedure using a check sheet and feedback by both mentors and a professor. Twenty-three Lap-LHx procedures performed during the study period were divided into two groups: those performed by young non-board-certified surgeons (n = 9) and those performed by senior board-certified surgeons (n = 14). The blood loss and operative time were similar in the young surgeon (194 g and 336 min, respectively) and senior surgeon groups (208 g and 322 min, respectively). Our standardized Lap-LHx procedure and stepwise training to perform it enable young surgeons to perform Lap-LHx as confidently and safely as more experienced surgeons. (Link to Publication Site) ● Publication site (DOI): 10.1007/s00464-016-5273-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27928671 ● Search Scopus @ Elsevier (PMID): 27928671 ● Search Scopus @ Elsevier (DOI): 10.1007/s00464-016-5273-3 (DOI: 10.1007/s00464-016-5273-3, PubMed: 27928671)
3.	Shinichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Masato Yoshikawa, Hiroki Teraoku and Mitsuo Shimada : Liver regeneration after splenectomy in patients with liver cirrhosis., Hepatology Research, Vol.46, No.5, 443-449, Oct. 2016. (Summary) Splenectomy is a well-known procedure to improve thrombocytopenia and liver function in patients with liver cirrhosis (LC). However, the effect of splenectomy on liver regeneration remains unclear. The aim of this study is to investigate the effect of splenectomy on liver regeneration. Twenty patients with LC who underwent splenectomy were included in this study. Liver and splenic volumes were measured by a 3-D simulation imaging system. Liver volume (LV) and clinicopathological data were compared before and 6 months after splenectomy. Thereafter, patients were divided into two groups: the elevated LV group and the reduced LV group. Patient characteristics were compared between the two groups. Postoperative LV was increased in 14 patients compared with the preoperative state. Thrombocytopenia, leukopenia, total bilirubin and prothrombin time were improved after splenectomy. In the elevated LV group, four patients exhibited improved Child-Pugh grades after splenectomy, whereas no patients demonstrated improvement in the reduced LV group. The elevated LV group exhibited high albumin level, good indocyanine green retention rate at 15 min and large splenic volume compared with the same measurements in the decreased group. Patients with larger spleen volumes and higher albumin values before splenectomy showed increased rates of LV after splenectomy. Splenectomy for patients with LC improved pancytopenia and liver function. Especially, in patients with large spleen and high albumin levels, considerable increases in LV and improved liver function were observed. (Link to Publication Site) ● Publication site (DOI): 10.1111/hepr.12573 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26428414 ● Search Scopus @ Elsevier (PMID): 26428414 ● Search Scopus @ Elsevier (DOI): 10.1111/hepr.12573 (DOI: 10.1111/hepr.12573, PubMed: 26428414)

Proceeding of International Conference:

1.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki and Mitsuo Shimada : Preoperative weight loss program for HCC patients with high body mass index in hepatectomy., APASL 2024 Kyoto(アジア太平洋肝臓学会), Kyoto, Mar. 2024.
2.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Yuhei Waki and Mitsuo Shimada : New onlocogical resectability of CRLM and multidisciplinary treatment strategy, APASL 2024 Kyoto(アジア太平洋肝臓学会), Kyoto, Mar. 2024.
3.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : Preoperative weight loss program for hepatocellular carcinoma patients with high body mass index in hepatectomy., ASCO-GI 2024, San Francisco, Jan. 2024.
4.	Hiroki Teraoku, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Shin-ichiro Yamada : Computed Tomography in Patients with Mass-Forming Intrahepatic Cholangiocarcinoma, IHPBA2020, Melbourne, Nov. 2020.
5.	Mitsuo Shimada, Hiroki Teraoku, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Chie Takasu and Shin-ichiro Yamada : Role of central hypovascularity in the hepatic arterial phase of dynamic CT on mass-forming intrahepatic cholangiocarcinoma., ASCO-GI, San Francisco, Jan. 2019. (Link to Publication Site) ● Publication site (DOI): 10.1200/JCO.2019.37.4_suppl.205 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2019.37.4_suppl.205 (DOI: 10.1200/JCO.2019.37.4_suppl.205)
6.	Satoru Imura, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Outcome of left lobe living-donor liver transplantation in Tokushima, 27th International Congress of The Transplantation Society(TTS), Jun. 2018.
7.	Yu Saitou, Rui Feng, Chie Takasu, Tetsuya Ikemoto, Shuichi Iwahashi, Hiroki Teraoku, Yuji Morine, Satoru Imura and Mitsuo Shimada : Establishment of effective differentiation protocols for insulin-producing cells using a new 3D culture system from adipose-tissue derived mesenchymal stem cell, 27th International Congress of The Transplantation Society(TTS), Jun. 2018.
8.	Toshiaki Yoshimoto, Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Hiroki Teraoku and Mitsuo Shimada : The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma: Experience of Sorafenib therapy combined with surgical resection or TACE, APASL STC2018, Yokohama, May 2018.
9.	Shuichi Iwahashi, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yu Saitou and Hiroki Teraoku : Reduced-port laparoscopic cholecystectomy for young surgeons, SAGES, Seattle, Apr. 2018.
10.	Satoru Imura, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Laparoscopic hemi-hepatectomy for liver tumor, SAGES, Seattle, Apr. 2018.
11.	Mitsuo Shimada, Shuichi Iwahashi, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku and Jun Higashijima : Usefulness of one-stop shop simulation for liver surgery using EOB-MRI., SAGES, Seattle, Apr. 2018.
12.	Yuuma Wada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Hiroki Teraoku, Shogo Oota, Jun Higashijima and Mitsuo Shimada : Significance of hypoxia inducible factor-1 expression in liver metastasis of colorectal cancer., ASCO-GI, San Francisco, Jan. 2018.
13.	Satoru Imura, Atsushi Takata, Toshiaki Yoshimoto, Masato Yoshikawa, Hiroki Teraoku, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Comparative analysis of the outcome between open and laparoscopic partial liver resection for hepatocellular carcinoma., SAGES, Houston, Mar. 2017.
14.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Hiroki Teraoku, Masato Yoshikawa and Jun Higashijima : Treatment strategy for colorectal liver metastases:Clinical impact of FOLFOXIRI regimen for unresectable cases., ASCO-GI, San Francisco, Jan. 2017. (Link to Publication Site) ● Publication site (DOI): 10.1200/JCO.2017.35.4_suppl.780 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2017.35.4_suppl.780 (DOI: 10.1200/JCO.2017.35.4_suppl.780)
15.	Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Masato Yoshikawa, Hiroki Teraoku and Jun Higashijima : Characteristics of intrahepatic cholangiocarcinoma according to tumor location., ASCO-GI, San Francisco, Jan. 2017. (Link to Publication Site) ● Publication site (DOI): 10.1200/JCO.2017.35.4_suppl.406 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2017.35.4_suppl.406 (DOI: 10.1200/JCO.2017.35.4_suppl.406)
16.	Masato Yoshikawa, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : Current status and effect of laparoscopic training for young surgeon, 40th World Congress of the International College of Surgeons (ICS 2016), Kyoto, Oct. 2016.
17.	Masato Yoshikawa, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : Elevated preoperative serum CEA levels in patients with HCC is associated with prognosis and EMT, 第8回日本・モンゴル消化器癌国際シンポジウム, ウランバートル, Aug. 2016.
18.	Yu Saitou, Atsushi Takata, Hiroki Teraoku, Masato Yoshikawa, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : The effect od HDACi in ADSC differentiation in to insulin producing cells., Transplantation Science Symposium (TSS) Asian Regional Meeting 2016, Tokyo, Apr. 2016.
19.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Hiroki Teraoku : Treatment strategy for intrahepatic cholangiocarcinoma: From optimal surgical management to adjuvant therapy., 2016 Gastrointestinal Cancers Symposium, San Francisco, Jan. 2016.

Proceeding of Domestic Conference:

1.	Yu Saitou, Tetsuya Ikemoto, Yuhei Waki, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : 脂肪由来幹細胞から分化誘導した肝細胞様細胞の免疫原性獲得に関する研究, 第23回日本再生医療学会総会, Mar. 2024.
2.	Takuya Tokunaga, Yuhei Waki, Hiroki Ishibashi, Hiroki Teraoku, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : ADSCから分化したSchwann cell-like cellが神経修復へ与える影響に関する基礎的検討, 第23回日本再生医療学会総会, Mar. 2024.
3.	Yuhei Waki, Yu Saitou, Tetsuya Ikemoto, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : 脂肪由来幹細胞から分化誘導した肝細胞様細胞の尿素サイクル異常症モデルマウスへの移植効果, 第23回日本再生医療学会総会, Mar. 2024.
4.	Tetsuya Ikemoto, Yu Saitou, Yuhei Waki, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : 再生医療を用いた新たな膵β細胞(insulin producing cell:IPC)移植戦略の樹立に関する研究, 第23回日本再生医療学会総会, Mar. 2024.
5.	Hiroki Teraoku, Yuhei Waki, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : 腫瘍関連マクロファージ(TAM)とのcrosstalkを介したLenvatinib耐性肝細胞癌における悪性度獲得機序, 第56回制癌剤適応研究会, Feb. 2024.
6.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki and Mitsuo Shimada : Atezolizmab+Bevacizumab療法ならびにTremelimumab+Durvalumab療法により縮小が得られ肝切除を施行し得たVp4を伴う進行肝細胞癌の一例, 第29回日本肝がん分子標的治療研究会, Jan. 2024.
7.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki and Mitsuo Shimada : 切除可能境界膵癌における集学的治療の意義, 第120回日本消化器病学会四国支部例会, Dec. 2023.
8.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 腹腔鏡下肝切除におけるPitfall -心房細動アブレーション後医原性心房中隔欠損を介した奇異性塞栓症-, 第36回日本内視鏡外科学会総会, Dec. 2023.
9.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku and Mitsuo Shimada : 最大腫瘍径×個数を用いた新たなresectabilityと治療戦略の提唱, 第45回日本肝臓学会西部会, Dec. 2023.
10.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 肝内胆管癌における新たな予後予測 - MRI拡散強調画像と腫瘍浸潤リンパ球 –, 第45回日本肝臓学会西部会, Dec. 2023.
11.	Yuuma Wada, Chie Takasu, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki, Hiroki Teraoku, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 肝細胞癌におけるエクソソームmiRNAを介したLenvatinib耐性機序の検討, 第34回日本消化器癌発生学会総会, Nov. 2023.
12.	Yuhei Waki, Yuji Morine, Hiroki Teraoku, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto and Mitsuo Shimada : 肝細胞癌微小環境におけるNrf2シグナルを介した癌細胞とTAMの相互作用, 第34回日本消化器癌発生学会総会, Nov. 2023.
13.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Yuhei Waki, Hiroki Teraoku and Mitsuo Shimada : 大建中湯(TU-100)のNASH発癌抑制効果に関する検討, 第34回日本消化器癌発生学会総会, Nov. 2023.
14.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki, Takayuki Noma and Mitsuo Shimada : 80歳以上の高齢者膵癌に対する膵頭十二指腸切除の治療成績, 第85回日本臨床外科学会総会, Nov. 2023.
15.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Yuhei Waki, Hiroki Teraoku and Mitsuo Shimada : 大腸癌多発肝転移における最大腫瘍径×個数を用いた肝切除基準と集学的治療方針の提唱, 第85回日本臨床外科学会総会, Nov. 2023.
16.	Yuhei Waki, Yuji Morine, Takayuki Noma, Hiroki Teraoku, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto and Mitsuo Shimada : 微小環境におけるエクソソームを介した薬剤肝細胞癌の悪性度増強と耐性機序の解明, 第61回日本癌治療学会学術集会, Oct. 2023.
17.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki, Takayuki Noma and Mitsuo Shimada : 再発肝細胞癌に対する肝切除成績, 第61回日本癌治療学会学術集会, Oct. 2023.
18.	Hiroki Teraoku : 膵体部術前化学療法中に急性膵炎による感染性脾動脈瘤からの腹腔内出血をきたした一例, 第15回日本Acute Care Surgery学会学術集会, Oct. 2023.
19.	Hiroki Teraoku : 膵・胆管合流異常における胆道上皮PD-L1発現の意義, 第59回日本胆道学会学術集会, Sep. 2023.
20.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki, Takayuki Noma and Mitsuo Shimada : 膵・胆管合流異常における胆道上皮PD-L1発現, 第46回日本膵・胆管合流異常研究会, Sep. 2023.
21.	Hiroki Teraoku, Yu Saitou, 杉本真樹, Yuji Morine, Shin-ichiro Yamada, Tetsuya Ikemoto and Mitsuo Shimada : 胆道手術における3D胆道造影Extended realityによる手術支援, 第17回肝癌治療ナビゲーション研究会, Aug. 2023.
22.	Yu Saitou, 杉本真樹, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 肝胆膵手術支援の新展開-Extended reality・ホログラム・メタバース-, 第50回日本膵切研究会, Aug. 2023.
23.	Hiroki Teraoku, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 症例, 第59回日本肝癌研究会, Jul. 2023.
24.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku and Mitsuo Shimada : 肝細胞癌における微小環境クロストークによるLenvatinib耐性機序の検討, 第59回日本肝癌研究会, Jul. 2023.
25.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Yuhei Waki, Tetsuya Ikemoto and Mitsuo Shimada : 肉眼的門脈浸潤を伴う進行肝細胞癌の治療戦略, 第59回日本肝癌研究会, Jul. 2023.
26.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Shoko Yamashita and Koichi Tsuneyama : 組織発生学的特徴からみた肝内胆管癌の病理診断, 第59回日本肝癌研究会, Jul. 2023.
27.	Yuhei Waki, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Takayuki Noma, Tetsuya Ikemoto and Mitsuo Shimada : 内科的治療後再発・遺残肝細胞に対するRescue肝切除の意義, 第78回日本消化器外科学会総会, Jul. 2023.
28.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki and Hiroki Teraoku : 徳島大学病院全体と消化器・移植外科のFRT回避に係る連携とOODAループ, 第78回日本消化器外科学会総会, Jul. 2023.
29.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Yuhei Waki, Hiroki Teraoku, Takayuki Noma and Mitsuo Shimada : EOBによる肝予備能評価と最大腫瘍径×個数を用いた肝切除限界の提唱, 第78回日本消化器外科学会総会, Jul. 2023.
30.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki, Takayuki Noma and Mitsuo Shimada : 高齢者膵癌に対する膵頭十二指腸切除術の適応と限界, 第78回日本消化器外科学会総会, Jul. 2023.
31.	Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Sonoko Yasui-Yamada, Hiroshi Sakaue, 鎌田基夢, Tetsuya Matsuura and Mitsuo Shimada : 肥満を有する肝細胞癌患者に対する術前栄養運動介入の有用性 - ERAS導入による手術成績の向上 –, 第78回日本消化器外科学会総会, Jul. 2023.
32.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki, Yuhei Waki, Tetsuya Ikemoto and Mitsuo Shimada : 肉眼的門脈浸潤を伴う進行肝細胞癌の治療戦略, 第78回日本消化器外科学会総会, Jul. 2023.
33.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto, Sonoko Yasui-Yamada, Hiroshi Sakaue, 鎌田基夢, Tetsuya Matsuura and Mitsuo Shimada : 肥満を有する肝細胞癌患者に対する術前栄養運動介入の有用性-ERAS導入による手術成績の向上 –, 日本外科代謝栄養学会第60回学術集会, Jul. 2023.
34.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki, 仲須千春 and Mitsuo Shimada : PD-L1 expression of biliary epithelium in pancreaticobiliary maljunction, 第35回日本肝胆膵外科学会学術集会, Jun. 2023.
35.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Yuhei Waki, Hiroki Teraoku and Mitsuo Shimada : New strategy for CRLM using Maximum Diameter x Number: MDN, 第35回日本肝胆膵外科学会学術集会, Jun. 2023.
36.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto, Shin-ichiro Yamada, 西麻希, Hiroshi Sakaue, 鎌田基夢, Tetsuya Matsuura and Mitsuo Shimada : Preoperative weight loss program for high body mass index patients undergoing liver resection for hepatocellular carcinoma - Surgical outcomes of ERAS protocol, 第35回日本肝胆膵外科学会学術集会, Jun. 2023.
37.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki and Hiroki Teraoku : Establishment of investigator initiated clinical trial as a future cell transplantation for to complement existing transplantations, 第35回日本肝胆膵外科学会学術集会, Jun. 2023.
38.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki, Yuhei Waki, Tetsuya Ikemoto and Mitsuo Shimada : Reconsideration of indication of hepatic for advanced hepatocellular carcinoma and significance of conversion surgery, 第35回日本肝胆膵外科学会学術集会, Jun. 2023.
39.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki, Takayuki Noma and Mitsuo Shimada : 肝細胞癌におけるNrf2/VEGFシグナルを介したTumor-associated macrophage (TAM)との相互作用, 第44回癌免疫外科研究会, Jun. 2023.
40.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku and Mitsuo Shimada : 術前の心構え「AWA spirits」に基づいたtraining systemによる肝胆膵外科の若手教育, 日本消化器病学会四国支部第119回例会, Jun. 2023.
41.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : StageIII/IVa肝細胞癌におけるMRI拡散強調画像ADC値とTumor infiltrative lymphocyte (TIL), 第59回日本肝臓学会総会, Jun. 2023.
42.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku and Mitsuo Shimada : 高齢者に対する肝胆膵手術におけるFrailtyの意義に関する検討, 第48回日本外科系連合学会学術集会, Jun. 2023.
43.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 進行肝細胞癌における至適肝切除適応の再考とConversion surgeryの意義, 第48回日本外科系連合学会学術集会, Jun. 2023.
44.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Yu Saitou, Shin-ichiro Yamada and Hiroki Teraoku : 徳島大学病院における医療安全管理上の患者アドボカシーの実情と展望, 第48回日本外科系連合学会学術集会, Jun. 2023.
45.	Hiroki Mori, Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Yuhei Waki, Hiroki Teraoku and Takayuki Noma : EOB予備能評価に基づいた至適肝切除, 第123回日本外科学会定期学術集会, Apr. 2023.
46.	Takayuki Noma, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 再発肝細胞癌に対する肝切除の意義, 第123回日本外科学会定期学術集会, Apr. 2023.
47.	Hiroki Teraoku, Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Sonoko Yasui-Yamada, 西麻希, Hiroshi Sakaue, 鎌田基夢, Tetsuya Matsuura and Mitsuo Shimada : 肝細胞癌における肥満患者への術前栄養運動介入の有用性, 第123回日本外科学会定期学術集会, Apr. 2023.
48.	Yuhei Waki, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and 仲須千春 : Lenvatinib耐性肝細胞癌における癌微小環境を介した悪性度獲得機序の解明, 第123回日本外科学会定期学術集会, Apr. 2023.
49.	Tetsuya Ikemoto, Mitsuo Shimada, Yu Saitou, Yuhei Waki, Hiroki Teraoku, Shin-ichiro Yamada and Yuji Morine : 再生医療によるインスリン産生細胞自家移植戦略は1型糖尿病治療を変える, 第123回日本外科学会定期学術集会, Apr. 2023.
50.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Yuhei Waki, Hiroki Teraoku and 仲須千春 : EOBによる肝予備能評価と最大腫瘍径×個数を用いた肝切除限界の提唱, 第123回日本外科学会定期学術集会, Apr. 2023.
51.	Yu Saitou, 杉本真樹, Yuji Morine, Tetsuya Ikemoto, Takuya Tokunaga, Shin-ichiro Yamada, Hiroki Teraoku, Takashi Iwata and Mitsuo Shimada : 消化器外科ナビゲーションの新展開 -Extended reality・ホログラム・メタバース –, 第123回日本外科学会定期学術集会, Apr. 2023.
52.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 進行肝細胞癌における至適肝切除適応の再考とConversion surgeryの意義, 第123回日本外科学会定期学術集会, Apr. 2023.
53.	Yuhei Waki, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : ADSCから分化したinsulin producing cell移植時の自己免疫による影響に関する検討, 第22回日本再生医療学会総会, Mar. 2023.
54.	Yu Saitou, 陳述海, Yuhei Waki, Tetsuya Ikemoto, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : ヒト脂肪由来間葉系幹細胞を用いた新たな肝細胞様細胞移植の樹立にむけて, 第22回日本再生医療学会総会, Mar. 2023.
55.	Tetsuya Ikemoto, Mitsuo Shimada, Yu Saitou, Yuhei Waki, Hiroki Teraoku, Shin-ichiro Yamada and Yuji Morine : 間葉系幹細胞を用いた新たなβ細胞補填治療法樹立に向けて, 第22回日本再生医療学会総会, Mar. 2023.
56.	Yuhei Waki, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : 再生医療によって作成されたinsulin producing cell移植後の自己免疫による影響に関する基礎的検討, 第50回日本膵・膵島移植学会学術集会, Mar. 2023.
57.	Tetsuya Ikemoto, Mitsuo Shimada, Yu Saitou, Yuhei Waki, Hiroki Teraoku, Yuuma Wada, Shin-ichiro Yamada and Yuji Morine : 再生医療を用いたβ細胞補填治療法に関する膵島移植とのクロストーク, 第50回日本膵・膵島移植学会学術集会, Mar. 2023.
58.	Hiroki Teraoku, Yuhei Waki, 仲須千春, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : Lenvatinib耐性肝細胞癌におけるNrf2を介した悪性度上昇と薬剤耐性獲得機序の検討, 第55回制癌剤適応研究会, Feb. 2023.
59.	Yuhei Waki, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and Mitsuo Shimada : Lenvatinib耐性肝細胞癌における癌微小環境を介した悪性度獲得と薬剤耐性獲得機序の解明, 第27回日本肝がん分子標的治療研究会, Jan. 2023.
60.	Shin-ichiro Yamada, Yuji Morine, Yu Saitou, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 肝細胞癌BCLC intermediate stageにおけるMaximum tumor diameter × number の意義, 第27回日本肝がん分子標的治療研究会, Jan. 2023.
61.	Hiroki Mori, Yuji Morine, Hiroki Ishibashi, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Shoko Yamashita, Koichi Tsuneyama and Mitsuo Shimada : 慢性炎症状態の膵・胆管合流異常におけるNLRP3活性化を介した腫瘍微小環境と発癌に関する検討, 第33回日本消化器癌発生学会総会, Nov. 2022.
62.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Yuhei Waki, Takayuki Noma and Mitsuo Shimada : 大腸癌肝転移におけるoncological/liver functional resectabilityの定義と集学的治療戦略, 第84回日本臨床外科学会総会, Nov. 2022.
63.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 進行肝細胞癌に対する外科切除成績とConversion surgeryの意義, 第84回日本臨床外科学会総会, Nov. 2022.
64.	Tetsuya Ikemoto, Mitsuo Shimada, Shin-ichiro Yamada, Hiroki Teraoku, Yu Saitou and Yuji Morine : de novo B型肝炎管理体制構築に向けた取り組み, 第84回日本臨床外科学会総会, Nov. 2022.
65.	Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Sonoko Yasui-Yamada, 西麻希, Hiroshi Sakaue, 鎌田基夢, Tetsuya Matsuura and Mitsuo Shimada : 肥満を有する肝細胞癌患者に対する術前栄養運動介入の有用性, 第118回日本消化器病学会四国支部例会, Nov. 2022.
66.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, 仲須千春, 髙橋叡, Takayuki Noma and Mitsuo Shimada : StageIII/IV肝細胞癌における拡散強調画像ADC値の意義, 第33回日本消化器癌発生学会総会, Nov. 2022.
67.	Chie Takasu, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and Mitsuo Shimada : 大腸癌肝転移における発育形式と予後に関する検討, 第84回日本臨床外科学会総会, Nov. 2022.
68.	Chie Takasu, 仲須千春, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Yuhei Waki and Mitsuo Shimada : Nrf2を基軸とした癌微小環境クロストークによる肝細胞癌Lenvatinib耐性機序解明に関する研究, 第33回日本消化器癌発生学会総会, Nov. 2022.
69.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : 肝細胞癌におけるlymphocyte/C-reactive protein ratio(LCR)の有用性, JDDW 2022, Oct. 2022.
70.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku and Mitsuo Shimada : 高齢者膵癌切除例におけるフレイルの影響に関する検討, JDDW 2022, Oct. 2022.
71.	仲須千春, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki, Hiroki Teraoku and Mitsuo Shimada : 肝細胞癌におけるNrf2に着目したレンバチニブ耐性獲得機序についての検討, 第60回日本癌治療学会学術集会, Oct. 2022.
72.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, 仲須千春 and Mitsuo Shimada : 肝癌微小環境におけるNrf2/VEGFシグナルを介した肝癌細胞とTAMの相互作用, 第60回日本癌治療学会学術集会, Oct. 2022.
73.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Toshiaki Yoshimoto, 西麻希, Hiroshi Sakaue and Mitsuo Shimada : 肥満肝細胞癌患者に対する術前栄養運動介入の有用性 -ERAS導入による手術成績の向上-, 第60回日本癌治療学会学術集会, Oct. 2022.
74.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku and Mitsuo Shimada : 高齢者膵癌切除例の予後におけるフレイルの影響に関する検討, 第60回日本癌治療学会学術集会, Oct. 2022.
75.	Tetsuya Ikemoto, Takuya Tokunaga, Yuhei Waki, Hiroki Teraoku, Shin-ichiro Yamada, Yu Saitou, Yuji Morine and Mitsuo Shimada : Schwann-like cell分化誘導による末梢神経損傷修復に関する基礎的検討, 第60回日本癌治療学会学術集会, Oct. 2022.
76.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 進行肝細胞癌に対する肝切除の意義, 第60回日本癌治療学会学術集会, Oct. 2022.
77.	Yuhei Waki, Yu Saitou, Tetsuya Ikemoto, 陳術海, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : ヒト脂肪由来間葉系幹細胞から肝細胞様細胞の創出-肝不全・代謝性肝疾患に対する肝移植から細胞治療へ, 第58回日本移植学会総会, Oct. 2022.
78.	Yu Saitou, Mitsuo Shimada, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto and Yuji Morine : 脳死肝移植ドナー不足解消にむけての普及啓発活動 - 医療系学生に対するドナーアクション(命の授業)の必要性 –, 第58回日本移植学会総会, Oct. 2022.
79.	Tetsuya Ikemoto, Mitsuo Shimada, Yu Saitou, Hiroki Teraoku, Shin-ichiro Yamada and Yuji Morine : 再生医療を用いた移植治療確立へ向けた戦略∼新たなβ細胞補充治療法, 第58回日本移植学会総会, Oct. 2022.
80.	Hiroki Mori, Yuji Morine, Hiroki Ishibashi, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Shoko Yamashita, Koichi Tsuneyama and Mitsuo Shimada : 慢性炎症化下の膵・胆管合流異常におけるNLRP3活性化を介した腫瘍微小環境と発癌に関する検討, 第45回日本膵・胆管合流異常研究会, Sep. 2022.
81.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : 肝細胞癌腫瘍微小環境におけるNrf2/VEGFシグナルを介した癌細胞とTAMの相互作用, 第81回日本癌学会学術総会, Sep. 2022.
82.	Takayuki Noma, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and Mitsuo Shimada : 再発膵癌に対する残膵切除の治療成績, 第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会, Sep. 2022.
83.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Takayuki Noma and Mitsuo Shimada : 大腸癌肝転移におけるresectabilityの定義と集学的治療戦略, 第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会, Sep. 2022.
84.	Yu Saitou, 杉本真樹, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku and Mitsuo Shimada : 術中ホログラム胆道造影を駆使した胆道手術支援, 第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会, Sep. 2022.
85.	Yu Saitou, 杉本真樹, Yuji Morine, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto and Mitsuo Shimada : 術中ホログラム胆道造影を駆使した胆道手術支援, 第16回肝癌治療ナビゲーション研究会, Sep. 2022.
86.	仲須千春, Mitsuo Shimada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and 沖川昌平 : MRI拡散強調画像から見たミラノ基準内肝細胞癌の予後予測に関する検討, 第77回日本消化器外科学会総会, Jul. 2022.
87.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : 膵癌残膵再発に対する残膵切除の治療成績, 第77回日本消化器外科学会総会, Jul. 2022.
88.	Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Toshiaki Yoshimoto, 西麻希, Hiroshi Sakaue and Mitsuo Shimada : 肥満を有する肝細胞癌患者に対する術前栄養運動介入の有用性, 第77回日本消化器外科学会総会, Jul. 2022.
89.	Tetsuya Ikemoto, Yu Saitou, Mitsuo Shimada, 沖川昌平, Hiroki Teraoku, Shin-ichiro Yamada and Yuji Morine : 再生医療を用いた細胞移植治療確立へ向けた戦略∼移植外科医・レシピエント双方の負担軽減という視点から, 第77回日本消化器外科学会総会, Jul. 2022.
90.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku and Mitsuo Shimada : 大腸癌肝転移におけるoncological/liver functional resectabilityの定義とBRに対する集学的治療戦略, 第77回日本消化器外科学会総会, Jul. 2022.
91.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 進行肝細胞癌に対する肝切除の意義, 第77回日本消化器外科学会総会, Jul. 2022.
92.	Chie Takasu, 仲須千春, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Yasuhiro Hamada, 沖川昌平 and Mitsuo Shimada : 肝細胞癌におけるmiRNA-132, 142-5pを介したLenvatinib耐性機序の検討, 第77回日本消化器外科学会総会, Jul. 2022.
93.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku and Mitsuo Shimada : 肝細胞癌におけるSorafenib/Lenvatinib耐性機序の検討, 第26回日本肝がん分子標的治療研究会, Jun. 2022.
94.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, 宮崎克己, Tetsuya Ikemoto and Mitsuo Shimada : 進行肝細胞癌に対する外科切除成績とConversion surgeryの意義, 第26回日本肝がん分子標的治療研究会, Jun. 2022.
95.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 進行肝細胞癌に対する肝切除を中心とした治療戦略, 第31回日本癌病態治療研究会, Jun. 2022.
96.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, 宮崎克己, Tetsuya Ikemoto and Mitsuo Shimada : 進行肝細胞癌に対する外科切除成績とConversion surgeryの意義, 第117回日本消化器病学会四国支部例会, Jun. 2022.
97.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Yu Saitou, Shin-ichiro Yamada and Hiroki Teraoku : 消化器・移植外科から発信する手術室医療安全, 第47回日本外科系連合学会学術集会, Jun. 2022.
98.	Hiroki Teraoku, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, 沖川昌平, Tetsuya Ikemoto and Mitsuo Shimada : Associations between the ADC values based on MRI diffusion-weighted images and tumor-infiltrative lymphocytes in Stage III / IV hepatocellular carcinoma, 第34回日本肝胆膵外科学会・学術集会, Jun. 2022.
99.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou and Hiroki Teraoku : Impact of frailty on resected pancreatic cancer in elderly patients, 第34回日本肝胆膵外科学会・学術集会, Jun. 2022.
100.	Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Masaaki Nishi, Hiroshi Sakaue and Mitsuo Shimada : Weight loss program for high body mass index patients undergoing liver resection for hepatocellular carcinoma, 第34回日本肝胆膵外科学会・学術集会, Jun. 2022.
101.	Tetsuya Ikemoto, Yu Saitou, Mitsuo Shimada, Hiroki Teraoku, Shin-ichiro Yamada and Yuji Morine : Establishment of investigator initiated clinical trial for insulin producing cells from ADSC with Tokushima protocol to complement pancreas/islet transplantation., 第34回日本肝胆膵外科学会・学術集会, Jun. 2022.
102.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : Role of surgical resection for advanced hepatocellular carcinoma focused on conversion surgery in MTA era, 第34回日本肝胆膵外科学会・学術集会, Jun. 2022.
103.	Yu Saitou, 杉本真樹, Yuji Morine, Tetsuya Ikemoto, Takuya Tokunaga, Shin-ichiro Yamada, Hiroki Teraoku and Mitsuo Shimada : 術中ホログラム胆道造影を駆使した胆道手術支援, 第31回日本コンピュータ外科学会大会, Jun. 2022.
104.	Hiroki Teraoku, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, 沖川昌平, Tetsuya Ikemoto and Mitsuo Shimada : Significance of the ADC values based on MRI DWI in Stage / HCC, 第67回国際外科学会日本部会総会, Jun. 2022.
105.	Chie Takasu, 仲須千春, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, 沖川昌平 and Mitsuo Shimada : 肝細胞癌におけるmiRNA-X,Yを介したLenvatinib耐性機序の検討, 第26回日本肝がん分子標的治療研究会, Jun. 2022.
106.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : 症例, 第58回日本肝癌研究会, May 2022.
107.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, 沖川昌平 and Mitsuo Shimada : 大腸癌肝転移におけるoncological/liver functional resectabilityの定義とBRに対する集学的治療戦略, 第58回日本肝癌研究会, May 2022.
108.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 進行肝細胞癌に対する肝切除の意義, 第58回日本肝癌研究会, May 2022.
109.	Yu Saitou, 杉本真樹, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku and Mitsuo Shimada : 術中ホログラム胆道造影を駆使した肝胆道手術支援, 第58回日本肝癌研究会, May 2022.
110.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 再発肝細胞癌に対する肝切除の意義, 第58回日本肝癌研究会, May 2022.
111.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, 沖川昌平 and 山下祥子 : 高齢者膵癌切除例におけるフレイルの影響に関する検討, 第108回日本消化器病学会総会, Apr. 2022.
112.	髙橋叡, Hiroki Teraoku, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, 沖川昌平, Tetsuya Ikemoto and Mitsuo Shimada : Stage III/IV 肝細胞癌におけるMRI拡散強調画像をもとにしたADC値の有用性に関する検討, 第122回日本外科学会定期学術集会, Apr. 2022.
113.	Hiroki Teraoku, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, 沖川昌平, Tetsuya Ikemoto and Mitsuo Shimada : Borderline resectableに着目した切除可能分類に基づく膵癌治療成績に関する検討, 第122回日本外科学会定期学術集会, Apr. 2022.
114.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, 沖川昌平 and Mitsuo Shimada : 膵癌切除例における早期再発の危険因子に関する検討, 第122回日本外科学会定期学術集会, Apr. 2022.
115.	荒川悠佑, Hiroki Teraoku, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 切除可能膵癌における術後予後予測因子としてのCRP・アルブミン比(CAR)の有用性, 第122回日本外科学会定期学術集会, Apr. 2022.
116.	Yu Saitou, 杉本真樹, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, 宮崎克己 and Mitsuo Shimada : 術中ホログラム胆道造影を駆使した胆道手術支援, 第122回日本外科学会定期学術集会, Apr. 2022.
117.	Tetsuya Ikemoto, Mitsuo Shimada, Yu Saitou, 沖川昌平, Hiroki Teraoku, Shin-ichiro Yamada and Yuji Morine : 自己脂肪から作成したインスリン産生細胞自家移植が拓く再生医療の未来, 第122回日本外科学会定期学術集会, Apr. 2022.
118.	Chie Takasu, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, 沖川昌平 and Mitsuo Shimada : 間葉系幹細胞から肝細胞様細胞の誘導におけるNrf2の働きに関する検討, 第122回日本外科学会定期学術集会, Apr. 2022.
119.	Tetsuya Ikemoto, Takuya Tokunaga, Yu Saitou, Shohei Okikawa, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : 脂肪由来幹細胞から分化誘導したSchwann-like cellに関する研究, 第21回日本再生医療学会総会, Mar. 2022.
120.	Shohei Okikawa, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, NAKASU Chiharu and Mitsuo Shimada : VEGF阻害はTAMの機能を減弱させる, 第25回日本肝がん分子標的治療研究会, Jan. 2022.
121.	Hiroki Teraoku, Yuji Morine, Shin-ichiro Yamada, Tetsuya Ikemoto, Yu Saitou and Mitsuo Shimada : 腹腔鏡下膵体尾部切除の手術手技と定型化, 第34回日本内視鏡外科学会総会, Dec. 2021.
122.	Chie Takasu, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and Mitsuo Shimada : 大腸癌肝転移における免疫逃避機構の働き, 第83回日本臨床外科学会総会, Nov. 2021.
123.	Hiroki Teraoku, Gao Luping, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : 肝細胞癌におけるNrf2-PINK-1axisを介したLenvatinib耐性機序の検討, 第32回日本消化器癌発生学会総会, Nov. 2021.
124.	Yu Saitou, 杉本真樹, Yuji Morine, Tetsuya Ikemoto, Takuya Tokunaga, Shin-ichiro Yamada, Hiroki Teraoku, Takashi Iwata and Mitsuo Shimada : 消化器外科におけるホログラム次世代手術支援, 第30回日本コンピュータ外科学会大会, Nov. 2021.
125.	Hiroki Teraoku, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : One stop shop を目指したEOB-MRIによる部分肝機能評価，切除限界予測と腫瘍悪性度の評価に関する検討, 第116回日本消化器病学会四国支部例会, Nov. 2021.
126.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : 再発膵癌に対する残膵切除の治療成績, 第83回日本臨床外科学会総会, Nov. 2021.
127.	Yu Saitou, 杉本真樹, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki and Mitsuo Shimada : Extended reality(VR・AR・MR)を駆使した手術ナビゲーション, 第83回日本臨床外科学会総会, Nov. 2021.
128.	Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki and Mitsuo Shimada : 地方から世界に通用する一流の外科医を目指した取り組み, 第83回日本臨床外科学会総会, Nov. 2021.
129.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki, Tetsuya Ikemoto and Mitsuo Shimada : 進行肝細胞癌に対する外科切除成績とConversion surgeryの意義, 第83回日本臨床外科学会総会, Nov. 2021.
130.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Yu Saitou, Shin-ichiro Yamada and Hiroki Teraoku : 外科医をも守る消化器・移植外科から発信する手術室医療安全, 第83回日本臨床外科学会総会, Nov. 2021.
131.	Shohei Okikawa, Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Katsuki Miyazaki and Mitsuo Shimada : DWI-MRIによる進行胆嚢癌の腫瘍悪性度評価, 第57回日本胆道学会学術集会, Oct. 2021.
132.	Shin-ichiro Yamada, Katsuki Miyazaki, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Shohei Okikawa, Shoko Yamashita and Mitsuo Shimada : 肝内胆管癌予後規定因子としての腫瘍浸潤リンパ球の意義, 第57回日本胆道学会学術集会, Oct. 2021.
133.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki and Mitsuo Shimada : 生体肝移植術後短期長期成績に関する検討, 第57回日本移植学会総会, Sep. 2021.
134.	Hiroki Teraoku, Yu Saitou, Tetsuya Ikemoto, Katsuki Miyazaki, Shin-ichiro Yamada, Yuji Morine, Masato Miyake, Seiichi Oyadomari and Mitsuo Shimada : ヒト脂肪由来間葉系幹細胞を基にした機能的肝細胞様細胞の分化誘導, 第57回日本移植学会総会, Sep. 2021.
135.	Tetsuya Ikemoto, Yu Saitou, Katsuki Miyazaki, Shohei Okikawa, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : 再生医療を用いたインスリン産生細胞自家移植による1型糖尿病根治治療確立へ向けた戦略, 第57回日本移植学会総会, Sep. 2021.
136.	Shin-ichiro Yamada, Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Hiroki Teraoku, 杉本真樹 and Mitsuo Shimada : Extended reality(VR・AR・MR)を駆使した手術ナビゲーション-マイクロ波手術デバイスAcrosurg®使用経験も含めて-, 第15回肝がんナビゲーション研究会, Sep. 2021.
137.	Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki and Mitsuo Shimada : DAA治療後SVR症例は発癌Potentialが高く進行病期に関与する, 第57回日本肝癌研究会, Jul. 2021.
138.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 進行肝細胞癌集学的治療における外科切除の役割:Conversion Surgery成績も含めて, 第57回日本肝癌研究会, Jul. 2021.
139.	TAKAHASHI Akira, Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Katsuki Miyazaki and Mitsuo Shimada : DWI-MRIによる進行胆嚢癌の腫瘍悪性度評価, 第76回日本消化器外科学会総, Jul. 2021.
140.	Yuuma Wada, Yuji Morine, Yu Saitou, Satoru Imura, Tetsuya Ikemoto, Masaaki Nishi, Shin-ichiro Yamada, Kazunori Tokuda, Hiroki Teraoku and Mitsuo Shimada : 癌微小環境における大建中湯の癌細胞増殖抑制効果, 第76回日本消化器外科学会総会, Jul. 2021.
141.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Shoko Yamashita, Katsuki Miyazaki and Mitsuo Shimada : 高齢者に対する肝胆膵手術におけるFrailtyの意義に関する検討, 第76回日本消化器外科学会総会, Jul. 2021.
142.	Yu Saitou, Maki Sugimoto, Yuji Morine, Tetsuya Ikemoto, Takuya Tokunaga, Hiroki Teraoku, Katsuki Miyazaki, Takashi Iwata and Mitsuo Shimada : Navigation of rectal and hepatobiliary pancreatic surgery with intraoperative hologram, 第76回日本消化器外科学会総会, Jul. 2021.
143.	Tetsuya Ikemoto, Kazunori Tokuda, Yu Saitou, Katsuki Miyazaki, Hiroki Teraoku, Shohei Okikawa, Shin-ichiro Yamada, Satoru Imura and Yuji Morine : 消化器外科領域の幹細胞トランスレーショナルリサーチにおける医工連携, 第76回日本消化器外科学会総会, Jul. 2021.
144.	Hiroki Teraoku, Yuji Morine, Shin-ichiro Yamada, Katsuki Miyazaki, Yu Saitou, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 両葉多発大腸癌肝転移に対する肝切除適応基準とConversion Surgery, 第76回日本消化器外科学会総会, Jul. 2021.
145.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 進行肝細胞癌集学的治療における外科切除の役割:Conversion Surgery成績も含めて, 第76回日本消化器外科学会総会, Jul. 2021.
146.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Shoko Yamashita, Katsuki Miyazaki and Mitsuo Shimada : 高齢者に対する肝胆膵手術におけるFrailtyの意義に関する検討, 第115回日本消化器病学会四国支部例会, Jun. 2021.
147.	Hiroki Teraoku, Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Katsuki Miyazaki : Significance of frailty for eldery patients in HPB surgery, 第33回日本肝胆膵外科学会学術集会, Jun. 2021.
148.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Kazunori Tokuda, Hiroki Teraoku, Shohei Okikawa, Shoko Yamashita, Katsuki Miyazaki and Mitsuo Shimada : Treatment strategy of multiple colorectal liver metastasis-Criteria for upfront surgery and Conversion Surgery-, 第33回日本肝胆膵外科学会学術集会, Jun. 2021.
149.	Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Maki Sugimoto and Mitsuo Shimada : Intraoperative support with 3D holographic cholangiography in biliary surgery, 第33回日本肝胆膵外科学会学術集会, Jun. 2021.
150.	Tetsuya Ikemoto, Kazunori Tokuda, Mitsuo Shimada, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and Katsuki Miyazaki : Clinical application of auto-transplantation of generated insulin-producing cells from ADSC with Tokushima protocol, 第33回日本肝胆膵外科学会学術集会, Jun. 2021.
151.	Hiroki Teraoku, Gao Luping, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Shohei Okikawa, Shoko Yamashita and Katsuki Miyazaki : 肝細胞癌におけるSorafenib耐性獲得機序に関する検討, 第121回日本外科学会定期学術集会, Apr. 2021.
152.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Hiroki Teraoku : 肝癌細胞におけるNrf2に着目した腫瘍関連マクロファージ活性化の検討, JDDW2018, Nov. 2018.
153.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Hiroki Teraoku : EOB-MRIは肝予備能を加味した術前simulationとして有用である, 第73回日本消化器外科学会総会, Jul. 2018.
154.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Hiroki Teraoku, 杉本真樹 and Mitsuo Shimada : 肝切除における解剖把握のためのVirtual Reality(VR)によるSimulationと術中手術支援, 第73回日本消化器外科学会総会, Jul. 2018.
155.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Yuuma Wada, Hiroki Teraoku and Shogo Oota : NCDデータからみた地方における消化器外科手術の特色と安全性評価に関する検討, 第73回日本消化器外科学会総会, Jul. 2018.
156.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou and Hiroki Teraoku : 肝内胆管癌に対する総合的治療戦略, 第73回日本消化器外科学会総会, Jul. 2018.
157.	Satoru Imura, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 手技定型化とstepwise training による安全な腹腔鏡下肝左葉切除, 第73回日本消化器外科学会総会, Jul. 2018.
158.	Hiroki Teraoku, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Yuuma Wada and Shogo Oota : CT動脈相の造影効果から見た肝内胆管癌の腫瘍悪性度に関する検討, 第73回日本消化器外科学会総会, Jul. 2018.
159.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou and Hiroki Teraoku : 長期予後に着目した膵全摘症例の検討-近年の化学療法の発展に伴う治療選択肢として-, 第49回日本膵臓学会大会, Jun. 2018.
160.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Hiroki Teraoku : 肝星細胞はIL-6を介して肝癌細胞の悪性度増強・転移促進に寄与する, 第54回日本肝癌研究会, Jun. 2018.
161.	Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Hiroki Teraoku and Mitsuo Shimada : 肝内胆管癌に対する総合的治療戦略, 第54回日本肝癌研究会, Jun. 2018.
162.	Shoko Iwahashi, Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Hiroki Teraoku, Mitsuo Shimada and Koichi Tsuneyama : 自然退縮を認めたInflammatory hepatocellular adenomaの一例, 第109回日本消化器病学会四国支部例会, Jun. 2018.
163.	Tetsuya Ikemoto, Mitsuo Shimada, Shinsuke Katoh, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Satoru Imura and Yuji Morine : 消化器・移植外科から発信する手術室の医療安全と効率化の両立, 第43回日本外科系連合学会学術集会, Jun. 2018.
164.	Yu Saitou, Satoru Imura, Hiroki Teraoku, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine, 杉本真樹 and Mitsuo Shimada : Simulation and intraoperative support with virtual reality (VR)for anatomical grasp in hepatectomy., 第30回日本肝胆膵外科学会学術集会, Jun. 2018.
165.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Hiroki Teraoku : Usefulness of 'one-stop shop' liver surgery simulation including estimation of total and regional liver functional reserve using EOB-MRI, 第30回日本肝胆膵外科学会学術集会, Jun. 2018.
166.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou and Hiroki Teraoku : Investigations for total pancreatectomy-focused on short-and long-term outcome-, 第30回日本肝胆膵外科学会学術集会, Jun. 2018.
167.	Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Hiroki Teraoku, Jun Higashijima, Chie Takasu and Mitsuo Shimada : Treatment guidance in resectable colorectal liver metastasis., 第30回日本肝胆膵外科学会学術集会, Jun. 2018.
168.	Satoru Imura, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Our educational system for safe and reliable hepatectomy., 第30回日本肝胆膵外科学会学術集会, Jun. 2018.
169.	Hiroki Teraoku, Tetsuya Ikemoto, Shogo Oota, Yuuma Wada, Yu Saitou, Shuichi Iwahashi, Satoru Imura, Yuji Morine and Mitsuo Shimada : Preoperative care and surgical management for elderly and/or high-risk patients, 第30回日本肝胆膵外科学会学術集会, Jun. 2018.
170.	Yuuma Wada, Yuji Morine, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, shogo ohta and Mitsuo Shimada : Significance of hypoxia inducible factor-1 expression in liver metastasis of colorectal cancer., 第30回日本肝胆膵外科学会学術集会, Jun. 2018.
171.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Hiroki Teraoku : 末梢血Tr1比率はIPMNの悪性度評価に有用である, 第27回日本癌病態治療研究会, May 2018.
172.	Shuichi Iwahashi, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yu Saitou and Hiroki Teraoku : 発光ダイオード(LED)の波長強度可変装置による肝細胞保護に関する研究, 第36回日本肝移植研究会, May 2018.
173.	Yu Saitou, Mitsuo Shimada, Satoru Imura, Hiroki Teraoku, Shuichi Iwahashi, Tetsuya Ikemoto and Yuji Morine : 医療系学生に対するDonor Actionの必要性- 移植医療理解・意思表示率向上にむけての取り組み –, 第36回日本肝移植研究会, May 2018.
174.	宮崎克己, Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Hiroki Teraoku, Koichi Tsuneyama and Mitsuo Shimada : 自然退縮を認めたInflammatory hepatocellular adenomaの一例, 第118回日本外科学会定期学術集会, Apr. 2018.
175.	Yu Saitou, Tetsuya Ikemoto, Shuichi Iwahashi, Hiroki Teraoku, Satoru Imura, Yuji Morine and Mitsuo Shimada : Epigallocatechin gallate(EGCG)による脂肪由来間葉系幹細胞(ADSC)からInsulin producing cell(IPC)への効率的な分化誘導に関する研究, 第118回日本外科学会定期学術集会, Apr. 2018.
176.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Hiroki Teraoku, 杉本真樹 and Mitsuo Shimada : 肝予備能を加味したOne Stop Shop SimulationとMixed realityによる新たなNavigation, 第118回日本外科学会定期学術集会, Apr. 2018.
177.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Hiroki Teraoku and Jun Higashijima : 同時性大腸癌肝転移に対する治療戦略, 第118回日本外科学会定期学術集会, Apr. 2018.
178.	Satoru Imura, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Lifting methodを駆使した安全・確実な開腹肝切除, 第118回日本外科学会定期学術集会, Apr. 2018.
179.	Yuuma Wada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Hiroki Teraoku, Shogo Oota and Mitsuo Shimada : 大腸癌肝転移におけるHypoxia Inducible Factor-1発現の意義 -肝転移巣・原発巣における腫瘍悪性度評価-, 第118回日本外科学会定期学術集会, Apr. 2018.
180.	Hiroki Teraoku, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Yuuma Wada and Shogo Oota : 肝内胆管癌の造影効果による腫瘍悪性度評価の検討, 第118回日本外科学会定期学術集会, Apr. 2018.
181.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Yuuma Wada and Hiroki Teraoku : Epigallocatechin-3-gallateはNrf2を介して膵島保護作用を有する, 第118回日本外科学会定期学術集会, Apr. 2018.
182.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Yuuma Wada, Hiroki Teraoku and Shogo Oota : 臨床応用を目指した間葉系幹細胞から創生されるインスリン産生細胞による糖尿病の治療法確立に関する研, 第118回日本外科学会定期学術集会, Apr. 2018.
183.	Hiroki Teraoku, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Yuuma Wada and Shogo Oota : Sorafenib投与症例におけるHCC長期生存例の検討, 第51回制癌剤適応研究会, Mar. 2018.
184.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Hiroki Teraoku : 肝星細胞はIL-9を介して肝癌細胞増強・転移促進に寄与する, 第51回制癌剤適応研究会, Mar. 2018.
185.	Shuichi Iwahashi, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yu Saitou and Hiroki Teraoku : 肝星細胞はIL-6を介して肝癌細胞増強・転移促進に寄与する, 第17回日本肝がん分子標的治療研究会, Jan. 2018.
186.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Hiroki Teraoku : 当科における腹腔鏡(補助)下膵体尾部切除術の検討, 第9回膵臓内視鏡外科研究会, Dec. 2017.
187.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Hiroki Teraoku, 杉本真樹 and Mitsuo Shimada : 若手医師による術前術中3Dsimulation画像を用いた腹腔鏡下手術の定型化, 第11回肝臓内視鏡外科研究会, Dec. 2017.
188.	Satoru Imura, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 手技定型化による安全な腹腔鏡下肝左葉切除, 第11回肝臓内視鏡外科研究会, Dec. 2017.
189.	Yuuma Wada, Tetsuya Ikemoto, Yuji Morine, Shuichi Iwahashi, Yu Saitou, Hiroki Teraoku, Shogo Oota, Satoru Imura and Mitsuo Shimada : Nef2-Keap1経路の膵島保護作用におけるEpigallocatechin-3-gallate(EGCG)の役割, 第47回日本創傷治癒学会, Nov. 2017.
190.	Shoko Iwahashi, Tetsuya Ikemoto, Yu Saitou, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Hiroki Teraoku and Mitsuo Shimada : 併存疾患多数のStageⅣa膵体部癌に対し集学的補助で化学療法jを導入し長期生存を得た一例, 第79回日本臨床外科学会総会, Nov. 2017.
191.	Shogo Oota, Yuuma Wada, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 初回切除後再発膵癌に対する再切除の有用性, 第79回日本臨床外科学会総会, Nov. 2017.
192.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Hiroki Teraoku and Shogo Oota : 超高齢者に対する肝切除の妥当性に関する検討 -85歳以上の超高齢者にも肝切除は安全に施行可能である, 第79回日本臨床外科学会総会, Nov. 2017.
193.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Hiroki Teraoku : Modified de-rotation法による完全動脈先行処理を用いた膵頭十二指腸切除術, 第79回日本臨床外科学会総会, Nov. 2017.
194.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Hiroki Teraoku, Chie Takasu and Jun Higashijima : 大腸癌切除不能両葉多発肝転移に対するFOLFOXIRI療法の有用性, 第79回日本臨床外科学会総会, Nov. 2017.
195.	Hiroki Teraoku : 大腸癌肝転移におけるFbxw7発現低下の意義, 第28回日本消化器癌発生学会総会, Nov. 2017.
196.	Hiroki Teraoku, Yu Saitou and Mitsuo Shimada : 肝胆膵外科手術における免疫指標を加味した新たな周術期栄養評価, 第108回日本消化器病学会四国支部例会, Nov. 2017.
197.	Hiroki Teraoku, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Yuuma Wada and Shogo Oota : One stop shopを目指したEOB-MRIによる部分切除術肝機能評価, 第26回日本コンピュータ外科学会大会, Oct. 2017.
198.	Yuuma Wada, Yuji Morine, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Shuichi Iwahashi, Hideya Kashihara, Chie Takasu, Yu Saitou, Daichi Ishikawa, Hiroki Teraoku, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 青色LED光は光受容体(opsin3)を介し癌細胞増殖を抑制する, 第55回日本癌治療学会学術集会, Oct. 2017.
199.	Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Hiroki Teraoku and Mitsuo Shimada : 肝内胆管癌における局在・浸潤形式別悪性度, 第55回日本癌治療学会学術集会, Oct. 2017.
200.	Shuichi Iwahashi, AHMAD AMMAR GHAIBEH, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Hiroki Teraoku : 人工知能を用いた肝細胞癌再発予測因子の検討, 第55回日本癌治療学会学術集会, Oct. 2017.
201.	Yu Saitou, Satoru Imura, Yuji Morine, Shogo Oota, Hiroki Teraoku, Shuichi Iwahashi, Tetsuya Ikemoto and Mitsuo Shimada : 肝切除におけるVirtual Reality(VR) 画像を駆使した胆管解剖把握のための術中Navigation System, 第12回肝癌治療シミュレーション研究会, Sep. 2017.
202.	Tetsuya Ikemoto, Mitsuo Shimada, Daichi Ishikawa, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Satoru Imura and Yuji Morine : IL driven IL-10 Tr1細胞による細胞レベルのRO/R1手術達成評価に関する検討, 第76回日本癌学会学術総会, Sep. 2017.
203.	Hiroki Teraoku, Tetsuya Ikemoto, Yuuma Wada, Shogo Oota, Yu Saitou, Shuichi Iwahashi, Satoru Imura, Yuji Morine, Mitsuo Shimada and Koichi Tsuneyama : 単純性嚢胞との鑑別に苦慮したnonmucinous cyctadenoma の1例, 第67回日本消化器画像診断研究会, Sep. 2017. (Keyword) 第67回日本消化器画像診断研究会
204.	Hiroki Teraoku, Tetsuya Ikemoto, Yuji Morine, Shuichi Iwahashi, Yu Saitou, Yuuma Wada, Shogo Oota, Satoru Imura and Mitsuo Shimada : Nrf2-Keap1制御系を介したEpigallocatechin-3-gallate(EGCG)による膵島保護作用に関する検討, 第53回日本移植学会総会, Sep. 2017.
205.	Tetsuya Ikemoto, Mitsuo Shimada, Satoru Imura, Yuji Morine, Shuichi Iwahashi, Yu Saitou and Hiroki Teraoku : 膵島移植に対するブレイクスルーとしてのAdipose tissue derived stem cellsからの効果的Insulin-producing cells創生, 第53回日本移植学会総会, Sep. 2017.
206.	Yu Saitou, Mitsuo Shimada, Satoru Imura, Hiroki Teraoku, Shuichi Iwahashi, Tetsuya Ikemoto and Yuji Morine : 脳死肝移植を推進するための学生に対するDonor Actionの必要性について, 第53回日本移植学会総会, Sep. 2017.
207.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Hiroki Teraoku : 赤色発光ダイオード(LED)は肝細胞保護作用を有する, 第255回徳島医学会学術集会, Aug. 2017.
208.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Masato Yoshikawa and Hiroki Teraoku : 肝内胆管癌における局在・浸潤形式別悪性度, 第72回日本消化器外科学会総会, Jul. 2017.
209.	Satoru Imura, Masato Yoshikawa, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 高度門脈侵襲陽性肝癌に対する集学的治療戦略, 第72回日本消化器外科学会総会, Jul. 2017.
210.	Hiroki Teraoku, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Masato Yoshikawa, Toshiaki Yoshimoto, Atsushi Takata and Koichi Tsuneyama : 症例, 第53回日本肝癌研究会, Jul. 2017.
211.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Hiroki Teraoku : 超高齢者に対する肝切除の妥当性に関する検討, 第53回日本肝癌研究会, Jul. 2017.
212.	Satoru Imura, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : ntermediate stage肝癌に対する肝切除の有用性, 第53回日本肝癌研究会, Jul. 2017.
213.	Shoko Iwahashi, Tetsuya Ikemoto, Mitsuo Shimada, Masato Yoshikawa, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Satoru Imura, Yuji Morine and Koichi Tsuneyama : 単純性嚢胞との鑑別に苦慮した極めて稀な膵嚢胞の1例, 第42回日本外科系連合学会学術集会, Jun. 2017.
214.	Tetsuya Ikemoto, Mitsuo Shimada, Shinsuke Katoh, Masato Yoshikawa, Hiroki Teraoku, Yu Saitou, Shuichi Iwahashi, Satoru Imura and Yuji Morine : 徳島大学病院GRMからみた手術室安全管理の取り組み, 第42回日本外科系連合学会学術集会, Jun. 2017.
215.	Yu Saitou, Hiroki Teraoku, Shuichi Iwahashi, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 肝内胆管癌におけるSFRP1発現低下は予後不良因子となる, 第16回日本肝がん分子標的治療研究会, Jun. 2017.
216.	Shogo Oota, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou and Hiroki Teraoku : 超高齢者に対する肝切除の妥当性に関する検討-85歳以上の超高齢者にも安全に施行可能である-, 第107回日本消化器病学会四国支部例, Jun. 2017.
217.	Shuichi Iwahashi, AHMAD AMMAR GHAIBEH, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa and Hiroki Teraoku : Predictability of postoperative recurrence on hepatocellular carcinoma through the alternating decision tree, 第29回日本肝胆膵外科学会学術集会(第6回アジア太平洋肝胆膵学会), Jun. 2017.
218.	Hiroki Teraoku, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou and Masato Yoshikawa : EOB-MRI is useful for `one stop shop` modality based on functional liver volume, 第29回日本肝胆膵外科学会学術集会(第6回アジア太平洋肝胆膵学会), Jun. 2017.
219.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Masato Yoshikawa and Hiroki Teraoku : Treatment strategy for colorectal liver matastasis-Surgical criteria for initially resectable and assessment toward conversion for unresectable cases-, 第29回日本肝胆膵外科学会学術集会(第6回アジア太平洋肝胆膵学会, Jun. 2017.
220.	Satoru Imura, Atsushi Takata, Toshiaki Yoshimoto, Masato Yoshikawa, Hiroki Teraoku, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Liver resection for hepatocellular carcinoma of BCLC intermediate stage, 第29回日本肝胆膵外科学会学術集会(第6回アジア太平洋肝胆膵学会), Jun. 2017.
221.	Hiroki Teraoku, Mitsuo Shimada, Tetsuya Ikemoto, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Masato Yoshikawa and Toshiaki Yoshimoto : 当科における膵全摘症例の検討-術後短期成績・長期予後の両面に着目して-, 第117回日本外科学会定期学術集会, Apr. 2017.
222.	川下陽一郎, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Daichi Ishikawa, Masato Yoshikawa, Atsushi Takata, Toshiaki Yoshimoto, Hiroki Teraoku and Mitsuo Shimada : 肝内胆管癌におけるHSF1発現の意義, 第117回日本外科学会定期学術集会, Apr. 2017.
223.	Satoru Imura, Atsushi Takata, Toshiaki Yoshimoto, Masato Yoshikawa, Hiroki Teraoku, Daichi Ishikawa, Yu Saitou, Chie Takasu, Shuichi Iwahashi, Jun Higashijima, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 肝切除シミュレーション・ナビゲーションを駆使した若手教育法の確立, 第117回日本外科学会定期学術集会, Apr. 2017.
224.	Satoru Imura, Masato Yoshikawa, Hiroki Teraoku, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 定型化と教育システムがもたらす安全な腹腔鏡下左葉切除, 第29回日本内視鏡外科学会総会, Dec. 2016.
225.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Hiroki Teraoku, Masato Yoshikawa, Chie Takasu, Yusuke Arakawa and Jun Higashijima : 大腸癌切除不能多発肝転移に対する治療戦略, 第78回日本臨床外科学会総会, Nov. 2016.
226.	Satoru Imura, Masato Yoshikawa, Hiroki Teraoku, Daichi Ishikawa, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : グリソン一括による肝門処理のコツとピットフォール, 第78回日本臨床外科学会総会, Nov. 2016.
227.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Daichi Ishikawa, Masato Yoshikawa, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : 末梢血Tr1細胞とFoxp3調節性T細胞は担癌状態におけるバイオメーカーとして有用である, 第54回日本癌治療学会学術集会, Oct. 2016.
228.	Daichi Ishikawa, Hiroki Teraoku, Atsushi Takata, Masato Yoshikawa, Chie Takasu, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 転移性肝癌における腫瘍悪性度制御因子としてのTHBS-1の役割, 第27回日本消化器癌発生学会総会, Sep. 2016.
229.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Daichi Ishikawa, Hiroki Teraoku and Masato Yoshikawa : 肝内胆管癌の腫瘍悪性度評価と制御の可能性, 第27回日本消化器癌発生学会総会, Sep. 2016.
230.	Yu Saitou, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : Boot Camp in Tokushima University., 第71回日本消化器外科学会総会, Jul. 2016.
231.	Yu Saitou, Atsushi Takata, Hiroki Teraoku, Masato Yoshikawa, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : The analysis in non-tumor liver tissue to prevent the recurrence after curative treatment of hepatocellular carcinoma., 第71回日本消化器外科学会総会, Jul. 2016.
232.	Tetsuya Ikemoto, Mitsuo Shimada, Satoru Imura, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Hiroki Teraoku : A new strategy forachieving effective islet transplantation with adipose tissue derved stem cells., 第71回日本消化器外科学会総会, Jul. 2016.
233.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Toshihiro Nakao, Yuji Morine, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto and Hiroki Teraoku : 青色LED光は癌細胞増殖を抑制する., 第71回日本消化器外科学会総会, Jul. 2016.
234.	Yu Saitou, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 脳死肝移植を推進するための学生に対するドナーアクションの必要性について., 第34回日本肝移植研究会, Jul. 2016.
235.	Yu Saitou, Sonoko Yasui, Masato Yoshikawa, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yasuhiro Hamada and Mitsuo Shimada : 肝硬変合併肝切除症例における栄養・免疫状態の特徴, 第52回日本肝癌研究会, Jul. 2016.
236.	Toshiaki Yoshimoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Masato Yoshikawa and Atsushi Takata : 症例, 第52回日本肝癌研究会, Jul. 2016.
237.	Satoru Imura, Masato Yoshikawa, Hiroki Teraoku, Daichi Ishikawa, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Intermediate stageの肝癌に対する肝切除は有効か?, 第52回日本肝癌研究会, Jul. 2016.
238.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and Masato Yoshikawa : 肝内胆管癌における発生部位別悪性度., 第52回日本肝癌研究会, Jul. 2016.
239.	Atsushi Takata, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yusuke Arakawa, Shuichi Iwahashi, Daichi Ishikawa, Masato Yoshikawa, Hiroki Teraoku and Toshiaki Yoshimoto : HCCに対して初回RFA治療早期にリンパ節再発をきたし外科的切除を施行した症例., 第41回日本外科系連合学会学術集会, Jun. 2016.
240.	Yu Saitou, Atsushi Takata, Masato Yoshikawa, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : PDに対するModified de-rotationを用いた``Complate artery-firstn approach''., 第41回日本外科系連合学会学術集会, Jun. 2016.
241.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : EOB-MRIを用いた機能的肝容積による新たな肝切除基準., 第28回日本肝胆膵外科学会・学術集会, Jun. 2016.
242.	Tetsuya Ikemoto, Mitsuo Shimada, Daichi Ishikawa, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and Masato Yoshikawa : Tr1細胞とFoxp3調節性T細胞による膵嚢胞性疾患に関する正確な免疫学的指標探索に関する研究., 第28回日本肝胆膵外科学会・学術集会, Jun. 2016.
243.	Yu Saitou, Atsushi Takata, Hiroki Teraoku, Masato Yoshikawa, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 胆道癌術後肝内再発に対する肝切除導入効果の検証., 第28回日本肝胆膵外科学会・学術集会, Jun. 2016.
244.	Masato Yoshikawa, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Atsushi Takata, Toshiaki Yoshimoto and Mitsuo Shimada : 当科における胆道再建における肝管空腸吻合法の工夫., 第28回日本肝胆膵外科学会・学術集会, Jun. 2016.
245.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa, Chie Takasu, Jun Higashijima, 川下陽一郎, Atsushi Takata, Toshiaki Yoshimoto, Satoru Imura and Mitsuo Shimada : 大腸癌肝転移肝切除症例におけるThrombospondin1(THBS)発現の意義とその分子メカニズムの検討., 第28回日本肝胆膵外科学会・学術集会, Jun. 2016.
246.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Daichi Ishikawa, Hiroki Teraoku, Masato Yoshikawa and Jun Higashijima : 大腸癌多発肝転移に対する長期生存を目指した治療戦略., 第28回日本肝胆膵外科学会・学術集会, Jun. 2016.
247.	Yu Saitou, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 徳島におけるABO不適合生体肝移植症例の成績., 第42回日本急性肝不全研究会, May 2016.
248.	Hiroki Teraoku, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Higashijima, 川下陽一郎, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Masato Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : 転移性肝癌における腫瘍悪性度制御因子としてのHIF-1の役割., 第102回日本消化器病学会総会, Apr. 2016.
249.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Hiroki Teraoku, Toshiaki Yoshimoto, Atsushi Takata and Chie Takasu : EOB-MRIを用いた新たな肝切除基準の可能性, 第102回日本消化器病学会総会, Apr. 2016.
250.	Kouzou Yoshikawa, Mitsuo Shimada, Toshihiro Nakao, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Masato Yoshikawa, Hiroki Teraoku, Toshiaki Yoshimoto and Atsushi Takata : 直腸癌術前CRT症例におけるKi-67, Survivin発現の意義, 第102回日本消化器病学会総会, Apr. 2016.
251.	Shogo Oota, Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Kouzou Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : 胆道癌術後肝内再発に対する肝切除導入効果の検証, 第116回日本外科学会定期学術集会, Apr. 2016.
252.	Shoko Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Higashijima, 川下陽一郎, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Masato Yoshikawa, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : 急速な進展を来したラブドイド様退形成性癌の一例., 第116回日本外科学会定期学術集会, Apr. 2016.
253.	関勇輔, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Higashijima, 川下陽一郎, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Masato Yoshikawa, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : RFA術後にリンパ節再発をきたし外科切除を施行した肝細胞癌の1例 -RFA術後再発におけるEMT誘導を介した悪性度獲得について-., 第116回日本外科学会定期学術集会, Apr. 2016.
254.	Atsushi Takata, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Masato Yoshikawa, Hiroki Teraoku, Toshiaki Yoshimoto and Chie Takasu : 腸管修復および癌幹細胞におけるSonic hedgehogの役割., 第116回日本外科学会定期学術集会, Apr. 2016.
255.	川下陽一郎, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Higashijima, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Hiroki Teraoku, Masato Yoshikawa, Atsushi Takata, Toshiaki Yoshimoto and Hirohisa Ogawa : 転移性肝癌におけるFbxw7低発現は再発予測因子である., 第116回日本外科学会定期学術集会, Apr. 2016.
256.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Takuya Tokunaga, Hiroki Teraoku, Masato Yoshikawa, Atsushi Takata and Mitsuo Shimada : 直腸癌術前CRT症例におけるKi-67，Survivin発現の意義, 第116回日本外科学会定期学術集会, Apr. 2016.
257.	Masato Yoshikawa, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : 肝細胞癌術後再発予後不良因子としてのCEAの意義, 第116回日本外科学会定期学術集会, Apr. 2016.
258.	Hiroki Teraoku, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Higashijima, 川下陽一郎, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Masato Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : 転移性肝癌における腫瘍悪性度制御因子としてのThrombospondin-1(THBS-1)の役割- 第2報 THBS-1制御メカニズムについて -, 第116回日本外科学会定期学術集会, Apr. 2016.
259.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Kouzou Yoshikawa, Hiroki Teraoku, Toshiaki Yoshimoto, Atsushi Takata and Chie Takasu : EOB-MRIを用いた新たな肝切除基準の可能性., 第116回日本外科学会定期学術集会, Apr. 2016.
260.	Yu Saitou, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : HDAC阻害剤は脂肪由来幹細胞からインスリン分泌細胞への分化誘導を促進する., 第116回日本外科学会定期学術集会, Apr. 2016.
261.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Daichi Ishikawa, Hiroki Teraoku and Masato Yoshikawa : 肝内胆管癌に対する至適術式と集学的治療., 第116回日本外科学会定期学術集会, Apr. 2016.
262.	布村俊幸, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Hiroki Teraoku, Masato Yoshikawa and Toshiaki Yoshimoto : 切除不能転移性肝癌を有する透析患者にFOLFOXIRI+Bevを施行しconversionが得られる1例., 第116回日本外科学会定期学術集会, Apr. 2016.
263.	Masaaki Nishi, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Hiroki Teraoku, Masato Yoshikawa and Toshiaki Yoshimoto : 膵癌細胞におけるResveratrolのShh pathwayを介した細胞増殖抑制効果, 第116回日本外科学会定期学術集会, Apr. 2016.
264.	Toshihiro Nakao, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Hiroki Teraoku, Masato Yoshikawa, Toshiaki Yoshimoto and Atsushi Takata : 進行大腸癌に対する新たな予後予測因子の検討., 第116回日本外科学会定期学術集会, Apr. 2016.
265.	Jun Higashijima, Takashi Iwata, Kouzou Yoshikawa, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : 側方転移を有する下部直腸癌への新たな治療戦略., 第116回日本外科学会定期学術集会, Apr. 2016.
266.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Hiroki Teraoku, Toshiaki Yoshimoto, Atsushi Takata and Masato Yoshikawa : 青色LED光は癌細胞増殖を抑制する., 第116回日本外科学会定期学術集会, Apr. 2016.
267.	Kouzou Yoshikawa, Mitsuo Shimada, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Masato Yoshikawa, Hiroki Teraoku, Toshiaki Yoshimoto and Atsushi Takata : 高齢者胃癌症例に対するリンパ節郭清範囲縮小の予後に及ぼす影響, 第88回日本胃癌学会総会, Mar. 2016.
268.	Tetsuya Ikemoto, Mitsuo Shimada, Satoru Imura, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa, Hiroki Teraoku and Toshiaki Yoshimoto : 脂肪由来幹細胞による膵島移植・膵島再生に関する新たな戦略, 第43回日本膵・膵島移植研究会, Mar. 2016.
269.	Yu Saitou, Masato Yoshikawa, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 36.3mm細径鉗子を用いたreduced port Lap-Cに関する検討, 第30回四国内視鏡外科研究会, Feb. 2016.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

Liver cancer drug resistance through Nrf2 dependence in tumor microenvironment (Project/Area Number: 21K16381 )
発光ダイオード（LED）の波長強度可変装置による癌細胞制御と細胞保護に関する研究 (Project/Area Number: 15K19858 )
Search by Researcher Number (80737106)

Designated Associate Professor : Teraoku, Hiroki

Research

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

Academic Paper (Unrefereed Paper):

Review, Commentary:

Proceeding of International Conference:

Proceeding of Domestic Conference:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)